Difference between revisions of "Team:Newcastle/Results"

Line 16: Line 16:
 
fieldset, form, label, legend,
 
fieldset, form, label, legend,
 
table, caption, tbody, tfoot, thead, tr, th, td,
 
table, caption, tbody, tfoot, thead, tr, th, td,
article, aside, canvas, details, embed,  
+
article, aside, canvas, details, embed,
figure, figcaption, footer, header, hgroup,  
+
figure, figcaption, footer, header, hgroup,
 
menu, nav, output, ruby, section, summary,
 
menu, nav, output, ruby, section, summary,
 
time, mark, audio, video {
 
time, mark, audio, video {
Line 109: Line 109:
 
<br />
 
<br />
 
<p><strong>
 
<p><strong>
Below is a diagram of our Sensynova Framework. Each part of the framework (e.g. detector modules) links to the relevant results.<br />
+
Below is a diagram of our Sensynova Framework. Clicking on each part of the framework (e.g. detector modules) links to the relevant results.<br />
 
<br />
 
<br />
 
Alternatively, at the <a href="https://2017.igem.org/Team:Newcastle/Results#myTab">bottom of this page are tabs</a> which will show you results for every part of the project
 
Alternatively, at the <a href="https://2017.igem.org/Team:Newcastle/Results#myTab">bottom of this page are tabs</a> which will show you results for every part of the project
Line 368: Line 368:
 
         <h1 style="font-family: Rubik"> Sarcosine Oxidase <span style="font-family:arial"></span><!--<button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#sox" aria-expanded="false" aria-controls="sox" style="margin-left: 1%"></button>--></h1>
 
         <h1 style="font-family: Rubik"> Sarcosine Oxidase <span style="font-family:arial"></span><!--<button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#sox" aria-expanded="false" aria-controls="sox" style="margin-left: 1%"></button>--></h1>
 
         <div id="sox">
 
         <div id="sox">
       
+
 
 
           <h2  style="font-size: 1em"> BioBricks used: <a href="http://parts.igem.org/Part:BBa_K2205003">BBa_K2205003 </a>(New), <a href="http://parts.igem.org/Part:BBa_K2205004"> BBa_K2205004 </a>(New) </h2>
 
           <h2  style="font-size: 1em"> BioBricks used: <a href="http://parts.igem.org/Part:BBa_K2205003">BBa_K2205003 </a>(New), <a href="http://parts.igem.org/Part:BBa_K2205004"> BBa_K2205004 </a>(New) </h2>
  
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
           <p>Sarcosine Oxidase (SOX) is an enzyme that oxidatively demethylates sarcosine to form glycine, hydrogen peroxide and formaldehyde (Figure 1) (Trickey et al. 1999). SOX was selected to be an example of a possible solution to one of the 5 problems in biosensor production that we identified - unconventional substrates. We defined an unconventional substrate as a substrate that we have little prior knowledge of but that can be adapted into something with an existing biosensor. SOX was specifically chosen to demonstrate that glyphosate, an unconventional substrate which there is not a lot information on, can be converted into formaldehyde which there are existing biosensors for (Ling and Heng 2010).  
+
           <p>Sarcosine Oxidase (SOX) is an enzyme that oxidatively demethylates sarcosine to form glycine, hydrogen peroxide and formaldehyde (Figure 1) (Trickey et al. 1999). SOX was selected to be an example of a possible solution to one of the 5 problems in biosensor production that we identified - unconventional substrates. We defined an unconventional substrate as a substrate that we have little prior knowledge of but that can be adapted into something with an existing biosensor. SOX was specifically chosen to demonstrate that glyphosate, an unconventional substrate which there is not a lot information on, can be converted into formaldehyde which there are existing biosensors for (Ling and Heng 2010).
 
           </br></br>
 
           </br></br>
 
           As part of our project, SOX was designed to be an ‘adapter’ that could link glyphosate into our framework via a formaldehyde detector module. This concept could then be applied to other molecules that have easily detectable substrates in their degradation pathways. The aim of this part of the project was to demonstrate that SOX can be expressed by <i>E. coli</i> cells and that when glyphosate is added SOX can convert it to formaldehyde to be detected via a biosensor.
 
           As part of our project, SOX was designed to be an ‘adapter’ that could link glyphosate into our framework via a formaldehyde detector module. This concept could then be applied to other molecules that have easily detectable substrates in their degradation pathways. The aim of this part of the project was to demonstrate that SOX can be expressed by <i>E. coli</i> cells and that when glyphosate is added SOX can convert it to formaldehyde to be detected via a biosensor.
Line 382: Line 382:
  
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Background Information </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Background Information </h2>
           <p>Glyphosate is a herbicide that works by blocking the activity of the enzyme enolpyruvylshikimate-3-phosphate synthase (EPSPS), which converts carbohydrates derived from glycolysis and the pentose phosphate pathway to plant metabolites and aromatic amino acids.  
+
           <p>Glyphosate is a herbicide that works by blocking the activity of the enzyme enolpyruvylshikimate-3-phosphate synthase (EPSPS), which converts carbohydrates derived from glycolysis and the pentose phosphate pathway to plant metabolites and aromatic amino acids.
 
           </br></br>
 
           </br></br>
           We attempted to design a system capable of glyphosate detection. With little information regarding mechanisms of glyphosate interactions with the cell, we could not design a simple system, representative of the majority of synthetic biology biosensor designs, in which a responsive transcription factor was able to affect the production of a reporter gene.  
+
           We attempted to design a system capable of glyphosate detection. With little information regarding mechanisms of glyphosate interactions with the cell, we could not design a simple system, representative of the majority of synthetic biology biosensor designs, in which a responsive transcription factor was able to affect the production of a reporter gene.
 
           </br></br>
 
           </br></br>
           The mining of transcriptome data has previously been used to find responsive DNA elements to a molecule of interest (Groningen 2012). Therefore, we analysed differences in transcriptome data between glyphosate sensitive and insensitive plants. A number of genes were found which were differently expressed. However, it was determined that it is more likely that this differential expression was not due to glyphosate directly, but rather the aromatic amino acid starvation caused by EPSPS inhibition by glyphosate, making these systems unsuitable for direct glyphosate detection. Various other systems we designed were also far from ideal, with high levels of complexity and reliance on native plant machinery.  
+
           The mining of transcriptome data has previously been used to find responsive DNA elements to a molecule of interest (Groningen 2012). Therefore, we analysed differences in transcriptome data between glyphosate sensitive and insensitive plants. A number of genes were found which were differently expressed. However, it was determined that it is more likely that this differential expression was not due to glyphosate directly, but rather the aromatic amino acid starvation caused by EPSPS inhibition by glyphosate, making these systems unsuitable for direct glyphosate detection. Various other systems we designed were also far from ideal, with high levels of complexity and reliance on native plant machinery.
 
           </br></br>
 
           </br></br>
 
           Through conversations with biosensor developers, we found that this problem was common in biosensor development - large amounts of often unavailable data is required for system design. For the Sensynova framework, we needed a more generic solution to this issue. Therefore, we expanded our search to look for biochemical reactions which we could monitor instead. This resulted in our concept of “adapter” devices which can alter difficult to sense molecules using biochemical reactions. </p>
 
           Through conversations with biosensor developers, we found that this problem was common in biosensor development - large amounts of often unavailable data is required for system design. For the Sensynova framework, we needed a more generic solution to this issue. Therefore, we expanded our search to look for biochemical reactions which we could monitor instead. This resulted in our concept of “adapter” devices which can alter difficult to sense molecules using biochemical reactions. </p>
  
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Design Stage </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Design Stage </h2>
           <p>To ensure the codon usage of our SOX protein was not differing significantly from the average codon usage of  <i> E. coli</i>, rare codons were removed from the sequence using the<a href="https://www.idtdna.com/CodonOpt">IDT codon optimisation tool</a> to produce high protein expression.  
+
           <p>To ensure the codon usage of our SOX protein was not differing significantly from the average codon usage of  <i> E. coli</i>, rare codons were removed from the sequence using the<a href="https://www.idtdna.com/CodonOpt">IDT codon optimisation tool</a> to produce high protein expression.
 
           </br></br>
 
           </br></br>
 
         <i> E. coli</i>  BL21-DE3 cells have higher levels of protein expression than DH5α cells and so were a more practical choice. This led to the expression of SOX being placed under the control of a T7 promoter due to BL21-DE3 cells producing T7 polymerase after the addition of IPTG.
 
         <i> E. coli</i>  BL21-DE3 cells have higher levels of protein expression than DH5α cells and so were a more practical choice. This led to the expression of SOX being placed under the control of a T7 promoter due to BL21-DE3 cells producing T7 polymerase after the addition of IPTG.
Line 426: Line 426:
 
           <p>After 8 hours of testing and left overnight, none of the samples had produced formaldehyde according to the testing strips. The testing strips detect a minimum formaldehyde concentration of 10 mg/L, so it was possible that formaldehyde had been produced but that there was too little of it to detect with the strips.</p>
 
           <p>After 8 hours of testing and left overnight, none of the samples had produced formaldehyde according to the testing strips. The testing strips detect a minimum formaldehyde concentration of 10 mg/L, so it was possible that formaldehyde had been produced but that there was too little of it to detect with the strips.</p>
 
           </br></br>
 
           </br></br>
         <p> We decided to add Sarcosine instead of Glyphosate to determine whether the part was working. Everything was repeated the same but instead we added 0 µl, 50 µl and 200 µl of Sarcosine at 0.9 g/50 ml.  
+
         <p> We decided to add Sarcosine instead of Glyphosate to determine whether the part was working. Everything was repeated the same but instead we added 0 µl, 50 µl and 200 µl of Sarcosine at 0.9 g/50 ml.
 
</br></br>
 
</br></br>
 
<div class="SOX"><img src="https://static.igem.org/mediawiki/2017/4/4b/T--Newcastle--SOX_testing.JPG" width="30%"/>
 
<div class="SOX"><img src="https://static.igem.org/mediawiki/2017/4/4b/T--Newcastle--SOX_testing.JPG" width="30%"/>
Line 449: Line 449:
  
 
             <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> References </h2>
 
             <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> References </h2>
           <p>Ling YP, Heng LY (2010). A Potentiometric Formaldehyde Biosensor Based on Immobilization of Alcohol Oxidase on Acryloxysuccinimide-modified Acrylic Microspheres. Sensors 10:9963-9981.  
+
           <p>Ling YP, Heng LY (2010). A Potentiometric Formaldehyde Biosensor Based on Immobilization of Alcohol Oxidase on Acryloxysuccinimide-modified Acrylic Microspheres. Sensors 10:9963-9981.
 
           </br></br>
 
           </br></br>
           Trickey P, Wagner MA, Jorns MS, Mathews FS (1999). Monomeric sarcosine oxidase: structure of a covalently flavinylated amine oxidizing enzyme. Structure 7:331-345.  
+
           Trickey P, Wagner MA, Jorns MS, Mathews FS (1999). Monomeric sarcosine oxidase: structure of a covalently flavinylated amine oxidizing enzyme. Structure 7:331-345.
 
           </br></br>
 
           </br></br>
 
         </div>
 
         </div>
Line 460: Line 460:
 
         <h1 style="font-family: Rubik"> Synthetic Promoter Library <button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#syn-prom-lib" aria-expanded="false" aria-controls="syn-prom-lib" style="margin-left: 1%"></button></h1>
 
         <h1 style="font-family: Rubik"> Synthetic Promoter Library <button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#syn-prom-lib" aria-expanded="false" aria-controls="syn-prom-lib" style="margin-left: 1%"></button></h1>
 
         <div id="syn-prom-lib" class="collapse">
 
         <div id="syn-prom-lib" class="collapse">
       
+
 
 
           <h2  style="font-size: 1em"> BioBricks used: BBa_0123456 (New), BBa_7890123 (Team_Name 20XX) </h2>
 
           <h2  style="font-size: 1em"> BioBricks used: BBa_0123456 (New), BBa_7890123 (Team_Name 20XX) </h2>
       
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
 
           <p>The Sensynova multicellular biosensor platform has been developed to overcome the limitations identified by our team [hyperlink to human practices] that hamper the success in biosensors development. One of these limits regards the lack of modularity and reusability of the various components. Our platform design, based on the expression of three main modules (Detector, Processor and Output) by three E.coli strains in co-culture, allows the switch of possible variances for each module and the production of multiple customised biosensors.
 
           <p>The Sensynova multicellular biosensor platform has been developed to overcome the limitations identified by our team [hyperlink to human practices] that hamper the success in biosensors development. One of these limits regards the lack of modularity and reusability of the various components. Our platform design, based on the expression of three main modules (Detector, Processor and Output) by three E.coli strains in co-culture, allows the switch of possible variances for each module and the production of multiple customised biosensors.
Line 484: Line 484:
 
           <p>Text goes here.</p>
 
           <p>Text goes here.</p>
 
         </div>
 
         </div>
       
+
 
 
         <hr>
 
         <hr>
       
+
 
 
         <h1 style="font-family: Rubik"> Arsenic Biosensor <button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#arsenic" aria-expanded="false" aria-controls="arsenic" style="margin-left: 1%"></button></h1>
 
         <h1 style="font-family: Rubik"> Arsenic Biosensor <button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#arsenic" aria-expanded="false" aria-controls="arsenic" style="margin-left: 1%"></button></h1>
 
         <div id="arsenic" class="collapse">
 
         <div id="arsenic" class="collapse">
       
+
 
 
           <h2  style="font-size: 1em"> BioBricks used: <a href="http://parts.igem.org/Part:BBa_J33201">BBa_J33201(Edinburgh )</a>, <a href="http://parts.igem.org/Part:BBa_K2205022">BBa_K2205022 (New)</a> </h2>
 
           <h2  style="font-size: 1em"> BioBricks used: <a href="http://parts.igem.org/Part:BBa_J33201">BBa_J33201(Edinburgh )</a>, <a href="http://parts.igem.org/Part:BBa_K2205022">BBa_K2205022 (New)</a> </h2>
         
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
 
           <p>The Sensynova multicellular biosensor platform has been developed to overcome the <a href="https://2017.igem.org/Team:Newcastle/HP/Silver">limitations identified by our team</a> that hamper the success in biosensor development. One of these limits regards the lack of modularity and reusability of the various components. Our platform design, based on the expression of three main modules (Detector, Processor and Reporter) by three  <i> E. coli</i>  strains in co-culture, allows the switch of possible variances for each module and the production of multiple customised biosensors.
 
           <p>The Sensynova multicellular biosensor platform has been developed to overcome the <a href="https://2017.igem.org/Team:Newcastle/HP/Silver">limitations identified by our team</a> that hamper the success in biosensor development. One of these limits regards the lack of modularity and reusability of the various components. Our platform design, based on the expression of three main modules (Detector, Processor and Reporter) by three  <i> E. coli</i>  strains in co-culture, allows the switch of possible variances for each module and the production of multiple customised biosensors.
Line 499: Line 499:
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Background Information </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Background Information </h2>
 
           <p>The part <a href="http://parts.igem.org/Part:BBa_J33201">BBa_J33201</a> was made by the Edinburgh team in 2006.</p>
 
           <p>The part <a href="http://parts.igem.org/Part:BBa_J33201">BBa_J33201</a> was made by the Edinburgh team in 2006.</p>
         
+
 
 
           <img src="https://static.igem.org/mediawiki/2017/b/b1/Vava1aa.png" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 70%">
 
           <img src="https://static.igem.org/mediawiki/2017/b/b1/Vava1aa.png" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 70%">
 
<p>
 
<p>
Line 505: Line 505:
  
 
</p>
 
</p>
         
+
 
 
           <p>This part consists of the promoter of the  <i> E. coli</i>  JM109 chromosomal arsenic detoxification operon (ars operon), including the ArsR repressor binding site and the <i>arsR</i> gene encoding the arsR repressor protein, together with its ribosome binding site. Addition of any other genes to the 3' end of this part will result in their expression being dependent on the presence of sodium arsenate or sodium arsenite. Arsenite or arsenite anion binds to the repressor protein ArsR, resulting in inability to repress the promoter. Based on our experiments, a concentration of 1 micromolar sodium arsenate in LB is sufficient for essentially full expression, though this will vary according to conditions.</p>
 
           <p>This part consists of the promoter of the  <i> E. coli</i>  JM109 chromosomal arsenic detoxification operon (ars operon), including the ArsR repressor binding site and the <i>arsR</i> gene encoding the arsR repressor protein, together with its ribosome binding site. Addition of any other genes to the 3' end of this part will result in their expression being dependent on the presence of sodium arsenate or sodium arsenite. Arsenite or arsenite anion binds to the repressor protein ArsR, resulting in inability to repress the promoter. Based on our experiments, a concentration of 1 micromolar sodium arsenate in LB is sufficient for essentially full expression, though this will vary according to conditions.</p>
  
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Design Stage </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Design Stage </h2>
         
+
 
 
         <table class="image_table" style="background:none">
 
         <table class="image_table" style="background:none">
 
<tr>
 
<tr>
Line 517: Line 517:
  
 
</td>
 
</td>
<td><div>  
+
<td><div>
  
 
           <a target="_blank" href="https://static.igem.org/mediawiki/2017/f/f6/Vave3.png">
 
           <a target="_blank" href="https://static.igem.org/mediawiki/2017/f/f6/Vave3.png">
Line 526: Line 526:
 
</tr>
 
</tr>
 
</table>
 
</table>
           </p>  
+
           </p>
         
+
 
         
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Implementation </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Implementation </h2>
         
+
 
 
<p>In order to introduce the Arsenic sensing part in the Sensinova framework, the part <a href="http://parts.igem.org/Part:BBa_K2205008">BBa_K2205008</a> containing the RBS B0034, the <i>lasI</i> coding sequence and the double terminator B0015 has been included in the design. The new part <a href="http://parts.igem.org/Part:BBa_K2205022">BBa_K2205022</a> presents biobrickable suffix and prefix and has been designed to have specific overhangs to be assembled in the plasmid pSB1C3 by Gibson assembly method. The part has been obtained by gBlock synthesis from IDT and subsequently assembled into the plasmid using NEB HI-Fi kit. The assembly mix was heat-shock transformed in competent DH5α and plated on Chloramphenicol LB plates. The colonies were tested through colony PCR and confirmed by sequencing.</p>
 
<p>In order to introduce the Arsenic sensing part in the Sensinova framework, the part <a href="http://parts.igem.org/Part:BBa_K2205008">BBa_K2205008</a> containing the RBS B0034, the <i>lasI</i> coding sequence and the double terminator B0015 has been included in the design. The new part <a href="http://parts.igem.org/Part:BBa_K2205022">BBa_K2205022</a> presents biobrickable suffix and prefix and has been designed to have specific overhangs to be assembled in the plasmid pSB1C3 by Gibson assembly method. The part has been obtained by gBlock synthesis from IDT and subsequently assembled into the plasmid using NEB HI-Fi kit. The assembly mix was heat-shock transformed in competent DH5α and plated on Chloramphenicol LB plates. The colonies were tested through colony PCR and confirmed by sequencing.</p>
  
 
           <img src="https://static.igem.org/mediawiki/2017/7/70/Vave4.png" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 70%">
 
           <img src="https://static.igem.org/mediawiki/2017/7/70/Vave4.png" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 70%">
         
+
 
 
<p>
 
<p>
 
         <b>Figure 4:</b> On the gel, colony PCR samples confirming the successful assembly of <a href="http://parts.igem.org/Part:BBa_K2205022">BBa_K2205022</a> into pSB1C3.
 
         <b>Figure 4:</b> On the gel, colony PCR samples confirming the successful assembly of <a href="http://parts.igem.org/Part:BBa_K2205022">BBa_K2205022</a> into pSB1C3.
Line 579: Line 579:
 
           <p>Brenner, K., Karing, D., Weiss, R. & Arnold, F. (2007) Engineered bidirectional communication mediates a consensus in a microbial biofilm consortium Proc Natl Acad Sci U S A 104(44): 17300 - 17304 </br> de Mora K, Joshi N, Balint BL, Ward FB, Elfick A, French CE. A pH-based biosensor for detection of arsenic in drinking water. Anal Bioanal Chem. 2011 May; 400(4):1031-9. Epub 2011 Mar 27.</p>
 
           <p>Brenner, K., Karing, D., Weiss, R. & Arnold, F. (2007) Engineered bidirectional communication mediates a consensus in a microbial biofilm consortium Proc Natl Acad Sci U S A 104(44): 17300 - 17304 </br> de Mora K, Joshi N, Balint BL, Ward FB, Elfick A, French CE. A pH-based biosensor for detection of arsenic in drinking water. Anal Bioanal Chem. 2011 May; 400(4):1031-9. Epub 2011 Mar 27.</p>
 
         </div>
 
         </div>
   <p>The preliminary qualitative assay above shows that there is no significant difference among the samples when inoculated with Arsenic in different concentration and the controls (with no Arsenic).    </p>  
+
   <p>The preliminary qualitative assay above shows that there is no significant difference among the samples when inoculated with Arsenic in different concentration and the controls (with no Arsenic).    </p>
 
         <hr>
 
         <hr>
       
+
 
 
         <h1 style="font-family: Rubik">Psicose Biosensor <span style="font-family: Arial">(</span><a href=#>Evry Paris-Saclay Collaboration</a><span style="font-family: Arial">)</span> <button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#psicose" aria-expanded="false" aria-controls="psicose" style="margin-left: 1%"></button></h1>
 
         <h1 style="font-family: Rubik">Psicose Biosensor <span style="font-family: Arial">(</span><a href=#>Evry Paris-Saclay Collaboration</a><span style="font-family: Arial">)</span> <button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#psicose" aria-expanded="false" aria-controls="psicose" style="margin-left: 1%"></button></h1>
 
         <div id="psicose" class="collapse">
 
         <div id="psicose" class="collapse">
       
+
 
 
           <h2  style="font-size: 1em"> BioBricks used: <a href="http://parts.igem.org/Part:BBa_K2205023">BBa_K2205023 (New)</a>, <a href="http://parts.igem.org/Part:BBa_K2448006">BBa_K2448006 (Evry Paris-Saclay 2017)</a>, <a href="http://parts.igem.org/Part:BBa_K2448011">BBa_K2448011  (Evry Paris-Saclay 2017)</a> </h2>
 
           <h2  style="font-size: 1em"> BioBricks used: <a href="http://parts.igem.org/Part:BBa_K2205023">BBa_K2205023 (New)</a>, <a href="http://parts.igem.org/Part:BBa_K2448006">BBa_K2448006 (Evry Paris-Saclay 2017)</a>, <a href="http://parts.igem.org/Part:BBa_K2448011">BBa_K2448011  (Evry Paris-Saclay 2017)</a> </h2>
       
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
 
           <p>The Sensynova multicellular biosensor platform has been developed to overcome the <a href="https://2017.igem.org/Team:Newcastle/HP/Silver">limitations identified by our team</a> that hamper the success in biosensor development. One of these limits regards the lack of modularity and reusability of the various components. Our platform design, based on the expression of three main modules (Detector, Processor and Output) by three <i>E.coli </i> strains in co-culture, allows the switch of possible variances for each module and the production of multiple customised biosensors.
 
           <p>The Sensynova multicellular biosensor platform has been developed to overcome the <a href="https://2017.igem.org/Team:Newcastle/HP/Silver">limitations identified by our team</a> that hamper the success in biosensor development. One of these limits regards the lack of modularity and reusability of the various components. Our platform design, based on the expression of three main modules (Detector, Processor and Output) by three <i>E.coli </i> strains in co-culture, allows the switch of possible variances for each module and the production of multiple customised biosensors.
Line 604: Line 604:
 
<i> <b> Evry Paris-Saclay Psicose Biosensor Design </i> </b> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
 
<i> <b> Evry Paris-Saclay Psicose Biosensor Design </i> </b> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
 
</p> </br>
 
</p> </br>
         
+
 
 
           <p>The inducible system works as detailed in the diagram below. When pTAC is induced due to the presence of IPTG, PsiR is transcribed and binds to the pPsitac promoter repressing the transcription of the mCherry protein. When psicose is present, the sugar binds to PsiR, freeing up the promoter and subsequently the colour output</p>
 
           <p>The inducible system works as detailed in the diagram below. When pTAC is induced due to the presence of IPTG, PsiR is transcribed and binds to the pPsitac promoter repressing the transcription of the mCherry protein. When psicose is present, the sugar binds to PsiR, freeing up the promoter and subsequently the colour output</p>
         
+
 
 
           <img src="https://static.igem.org/mediawiki/2017/e/ef/T--Newcastle--Lais--Evry--System--SBOL.png" class="img-fluid border border-dark rounded" style="margin: 2%">
 
           <img src="https://static.igem.org/mediawiki/2017/e/ef/T--Newcastle--Lais--Evry--System--SBOL.png" class="img-fluid border border-dark rounded" style="margin: 2%">
 
<p>
 
<p>
Line 612: Line 612:
 
<i> <b> SBOL Visual Detailing Evry Paris-Saclay Psicose Biosensor Design </i> </b> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
 
<i> <b> SBOL Visual Detailing Evry Paris-Saclay Psicose Biosensor Design </i> </b> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
 
</p></br>
 
</p></br>
         
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Design Stage </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Design Stage </h2>
 
           <p>In order to implement the psicose biosensor variant to the Sensynova platform, a design was created by replacing the IPTG sensing system in the original detector module with the construct detailed above, creating part K2205023.
 
           <p>In order to implement the psicose biosensor variant to the Sensynova platform, a design was created by replacing the IPTG sensing system in the original detector module with the construct detailed above, creating part K2205023.
Line 619: Line 619:
  
 
           <img src="https://static.igem.org/mediawiki/2017/2/28/T--Newcastle--Lais--Evry--SBOL.png" class="img-fluid border border-dark rounded" style="margin: 2%">
 
           <img src="https://static.igem.org/mediawiki/2017/2/28/T--Newcastle--Lais--Evry--SBOL.png" class="img-fluid border border-dark rounded" style="margin: 2%">
         
+
 
 
<p>
 
<p>
 
<b>Figure 3:</b> <!--- Insert image name between tags. ---->
 
<b>Figure 3:</b> <!--- Insert image name between tags. ---->
Line 625: Line 625:
 
</p></br>
 
</p></br>
 
           <p>Part K2205023 detailed above was designed using Benchling and ordered for synthesis through IDT. Using Benchling, virtual digestions and ligations were simulated resulting in the plasmid map detailed below.</p>
 
           <p>Part K2205023 detailed above was designed using Benchling and ordered for synthesis through IDT. Using Benchling, virtual digestions and ligations were simulated resulting in the plasmid map detailed below.</p>
         
+
 
 
           <a target="_blank" href="https://static.igem.org/mediawiki/2017/4/49/T--Newcastle--Lais--Evry--Plasmid--Map.png">
 
           <a target="_blank" href="https://static.igem.org/mediawiki/2017/4/49/T--Newcastle--Lais--Evry--Plasmid--Map.png">
 
           <img src="https://static.igem.org/mediawiki/2017/4/49/T--Newcastle--Lais--Evry--Plasmid--Map.png" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 40%">
 
           <img src="https://static.igem.org/mediawiki/2017/4/49/T--Newcastle--Lais--Evry--Plasmid--Map.png" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 40%">
Line 633: Line 633:
 
<i> <b><a href="http://parts.igem.org/Part:K2205023"> BBa_K2205023 </a>in PSB1C3 </i> </b> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
 
<i> <b><a href="http://parts.igem.org/Part:K2205023"> BBa_K2205023 </a>in PSB1C3 </i> </b> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
 
</p></br>
 
</p></br>
         
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Implementation </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Implementation </h2>
 
           <p>The Psicose detector construct obtained by gBlock synthesis has been designed to include required overhangs for Gibson assembly into the linearized plasmid pSB1C3.
 
           <p>The Psicose detector construct obtained by gBlock synthesis has been designed to include required overhangs for Gibson assembly into the linearized plasmid pSB1C3.
Line 655: Line 655:
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> References </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> References </h2>
 
           <p>iGEM Community. (2017). Team Evry Paris-Saclay 2017. [online] Available at: https://2017.igem.org/Team:Evry_Paris-Saclay [Accessed 30 Oct. 2017].</p>
 
           <p>iGEM Community. (2017). Team Evry Paris-Saclay 2017. [online] Available at: https://2017.igem.org/Team:Evry_Paris-Saclay [Accessed 30 Oct. 2017].</p>
         </div>
+
         </div>
       
+
 
 
       </div>
 
       </div>
 
       <div class="tab-pane fade" id="nav-processor" role="tabpanel" aria-labelledby="nav-processor-tab">
 
       <div class="tab-pane fade" id="nav-processor" role="tabpanel" aria-labelledby="nav-processor-tab">
Line 717: Line 717:
  
  
This culture is then co-cultured with the reporter cell. This reporter cell detects C4 AHL and expresses GFP in response.  
+
This culture is then co-cultured with the reporter cell. This reporter cell detects C4 AHL and expresses GFP in response.
 
  <br/><br/>
 
  <br/><br/>
<img class="FIM"  style="width:40%" src="https://static.igem.org/mediawiki/2017/b/bb/T--Newcastle--MP_Char1.jpeg"/>  
+
<img class="FIM"  style="width:40%" src="https://static.igem.org/mediawiki/2017/b/bb/T--Newcastle--MP_Char1.jpeg"/>
 
<br />
 
<br />
 
Figure 6: Initial test of the red and white fim switch strains which were spotted onto a lawn of the reporter strain (<a href="http://parts.igem.org/Part:BBa_K2205015">BBa_K2205015</a>).<br/>
 
Figure 6: Initial test of the red and white fim switch strains which were spotted onto a lawn of the reporter strain (<a href="http://parts.igem.org/Part:BBa_K2205015">BBa_K2205015</a>).<br/>
Line 751: Line 751:
 
</p>
 
</p>
  
       
+
 
 
         <hr>
 
         <hr>
 
         <!---------------------------------------------------------------->
 
         <!---------------------------------------------------------------->
Line 757: Line 757:
 
         <h1 style="font-family: Rubik"> Signal Tuners <button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#signal" aria-expanded="false" aria-controls="signal" style="margin-left: 1%"></button></h1>
 
         <h1 style="font-family: Rubik"> Signal Tuners <button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#signal" aria-expanded="false" aria-controls="signal" style="margin-left: 1%"></button></h1>
 
         <div id="signal" class="collapse">
 
         <div id="signal" class="collapse">
       
+
 
 
           <h2  style="font-size: 1em"> BioBricks used: <a href="http://parts.igem.org/Part:BBa_K2205024">BBa_K2205024 (New)</a>, <a href="http://parts.igem.org/Part:BBa_K2205025">BBa_K2205025 (New)</a>, <a href="http://parts.igem.org/Part:BBa_K2205027">BBa_K2205027 (New)</a>, <a href="http://parts.igem.org/Part:BBa_K2205028">BBa_K2205028 (New)</a>, <a href="http://parts.igem.org/Part:BBa_K274371">BBa_K274371 (Cambridge 2009)</a>, <a href="http://parts.igem.org/Part:BBa_K274381">BBa_K274381 (Cambridge 2009)</a> </h2>
 
           <h2  style="font-size: 1em"> BioBricks used: <a href="http://parts.igem.org/Part:BBa_K2205024">BBa_K2205024 (New)</a>, <a href="http://parts.igem.org/Part:BBa_K2205025">BBa_K2205025 (New)</a>, <a href="http://parts.igem.org/Part:BBa_K2205027">BBa_K2205027 (New)</a>, <a href="http://parts.igem.org/Part:BBa_K2205028">BBa_K2205028 (New)</a>, <a href="http://parts.igem.org/Part:BBa_K274371">BBa_K274371 (Cambridge 2009)</a>, <a href="http://parts.igem.org/Part:BBa_K274381">BBa_K274381 (Cambridge 2009)</a> </h2>
  
Line 778: Line 778:
 
<i> <b> Cambridge 2007 Amplifier System </i> </b> </h3> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
 
<i> <b> Cambridge 2007 Amplifier System </i> </b> </h3> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
 
</p></br>
 
</p></br>
         
+
 
 
           <p>The 2009 Cambridge iGEM team then re-designed these constructs to be PoPS converters, as image below taken from their wiki details, and generated a set sensitivity tuners corresponding to Cambridge 2007’s amplifiers.</p>
 
           <p>The 2009 Cambridge iGEM team then re-designed these constructs to be PoPS converters, as image below taken from their wiki details, and generated a set sensitivity tuners corresponding to Cambridge 2007’s amplifiers.</p>
 
           <img class="img-fluid border border-dark rounded" style="margin: 2%" style="margin: 2%" src="https://static.igem.org/mediawiki/2017/b/b9/T--Newcastle--Lais--ST--C2--SBOL.png"></img>
 
           <img class="img-fluid border border-dark rounded" style="margin: 2%" style="margin: 2%" src="https://static.igem.org/mediawiki/2017/b/b9/T--Newcastle--Lais--ST--C2--SBOL.png"></img>
         
+
 
 
<p>
 
<p>
 
  <h3><b>Figure 2:</b> <!--- Insert image name between tags. ---->
 
  <h3><b>Figure 2:</b> <!--- Insert image name between tags. ---->
 
<i> <b> Cambridge 2009 System Design </i> </b> </h3> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
 
<i> <b> Cambridge 2009 System Design </i> </b> </h3> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
 
</p></br>
 
</p></br>
       
+
 
 
           <h4 style="font-family: Rubik; text-align: left; margin-top: 1%">BBa_K274371 – P2 Phage Sensitivity Tuner</h4>
 
           <h4 style="font-family: Rubik; text-align: left; margin-top: 1%">BBa_K274371 – P2 Phage Sensitivity Tuner</h4>
 
           <p>This part is made up of an RBS (BBa_B0034), an org activator coding sequence (BBa_I746350) from P2 phage, the double terminator BBa_B0015 (made up of BBa_B0010 and BBa_B0012) and the inducible promoter PO (BBa_I746361) from P2 phage.</p>
 
           <p>This part is made up of an RBS (BBa_B0034), an org activator coding sequence (BBa_I746350) from P2 phage, the double terminator BBa_B0015 (made up of BBa_B0010 and BBa_B0012) and the inducible promoter PO (BBa_I746361) from P2 phage.</p>
Line 794: Line 794:
 
  <h3><b>Figure 3:</b> <!--- Insert image name between tags. ---->
 
  <h3><b>Figure 3:</b> <!--- Insert image name between tags. ---->
 
<i> <b> <a href="http://parts.igem.org/Part:BBa_K274371"> BBa_K274371</a> </i> </b> </h3> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
 
<i> <b> <a href="http://parts.igem.org/Part:BBa_K274371"> BBa_K274371</a> </i> </b> </h3> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
</p></br>        
+
</p></br>
 +
 
  
       
 
 
           <h4 style="font-family: Rubik; text-align: left; margin-top: 1%">BBa_K274381 – PSP3 Phage Sensitivity Tuner</h4>
 
           <h4 style="font-family: Rubik; text-align: left; margin-top: 1%">BBa_K274381 – PSP3 Phage Sensitivity Tuner</h4>
 
           <p>This part is made up of an RBS (BBa_B0034), a pag activator coding sequence (BBa_I746351) from PSP3 phage, the double terminator BBa_B0015 (made up of BBa_B0010 and BBa_B0012) and the inducible promoter PO (BBa_I746361) from P2 phage.</p>
 
           <p>This part is made up of an RBS (BBa_B0034), a pag activator coding sequence (BBa_I746351) from PSP3 phage, the double terminator BBa_B0015 (made up of BBa_B0010 and BBa_B0012) and the inducible promoter PO (BBa_I746361) from P2 phage.</p>
Line 812: Line 812:
 
<i> <b> SBOL Visual Detailing Processor Variants </i> </b> </h3> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
 
<i> <b> SBOL Visual Detailing Processor Variants </i> </b> </h3> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
 
</p></br>
 
</p></br>
         
+
 
 
           <p>Using Benchling, virtual digestions of the two sensitivity tuners and ligations to the part K2205010, the connector 1 receiver module, were carried out. These two new constructs were then virtual digested and ligated to the part K2205011, the connector 2 reporter module, resulting in the two plasmid maps detailed below; parts K2205024 and K2205025.</p>
 
           <p>Using Benchling, virtual digestions of the two sensitivity tuners and ligations to the part K2205010, the connector 1 receiver module, were carried out. These two new constructs were then virtual digested and ligated to the part K2205011, the connector 2 reporter module, resulting in the two plasmid maps detailed below; parts K2205024 and K2205025.</p>
 
           <a target="_blank" href="https://static.igem.org/mediawiki/2017/3/36/T--Newcastle--Lais--ST--C71--Map.png">
 
           <a target="_blank" href="https://static.igem.org/mediawiki/2017/3/36/T--Newcastle--Lais--ST--C71--Map.png">
Line 824: Line 824:
 
  <h3><b>Figure 6:</b> <!--- Insert image name between tags. ---->
 
  <h3><b>Figure 6:</b> <!--- Insert image name between tags. ---->
 
<i> <b> Parts<a href="http://parts.igem.org/Part:BBa_K2205024"> BBa_K2205024</a> and <a href="http://parts.igem.org/Part:BBa_K2205025"> BBa_K2205025</a> </i>(Click for larger images) </b> </h3> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
 
<i> <b> Parts<a href="http://parts.igem.org/Part:BBa_K2205024"> BBa_K2205024</a> and <a href="http://parts.igem.org/Part:BBa_K2205025"> BBa_K2205025</a> </i>(Click for larger images) </b> </h3> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
</p></br>        
+
</p></br>
  
  
Line 841: Line 841:
  
 
                 <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Conclusions and Future Work </h2>
 
                 <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Conclusions and Future Work </h2>
           <p>Due to time constraints, we lacked the time to characterise these parts into the Sensynova platform within the lab. The parts <a href="http://parts.igem.org/Part:BBa_K2205024"> BBa_K2205024</a> and <a href="http://parts.igem.org/Part:BBa_K2205025"> BBa_K2205025</a>, the parts <a href="http://parts.igem.org/Part:BBa_K274371"> BBa_K274371 </a> and <a href="http://parts.igem.org/Part:BBa_K274381"> BBa_K274381 </a> respectively as processing units of the platform, were been submitted to the iGEM registry for future work and characterisation by future teams.  
+
           <p>Due to time constraints, we lacked the time to characterise these parts into the Sensynova platform within the lab. The parts <a href="http://parts.igem.org/Part:BBa_K2205024"> BBa_K2205024</a> and <a href="http://parts.igem.org/Part:BBa_K2205025"> BBa_K2205025</a>, the parts <a href="http://parts.igem.org/Part:BBa_K274371"> BBa_K274371 </a> and <a href="http://parts.igem.org/Part:BBa_K274381"> BBa_K274381 </a> respectively as processing units of the platform, were been submitted to the iGEM registry for future work and characterisation by future teams.
 
           </br></br>
 
           </br></br>
 
The intermediate parts <a href="http://parts.igem.org/Part:BBa_K2205027"> BBa_K2205027</a> and <a href="http://parts.igem.org/Part:BBa_K2205028"> BBa_K2205028</a>, the parts <a href="http://parts.igem.org/Part:BBa_K274371"> BBa_K274371 </a> and <a href="http://parts.igem.org/Part:BBa_K274381"> BBa_K274381 </a> respectively resulted from the ligation to the first part of processing unit of the platform prior to the ligation to part of processing unit of the platform, were also submitted to the registry.
 
The intermediate parts <a href="http://parts.igem.org/Part:BBa_K2205027"> BBa_K2205027</a> and <a href="http://parts.igem.org/Part:BBa_K2205028"> BBa_K2205028</a>, the parts <a href="http://parts.igem.org/Part:BBa_K274371"> BBa_K274371 </a> and <a href="http://parts.igem.org/Part:BBa_K274381"> BBa_K274381 </a> respectively resulted from the ligation to the first part of processing unit of the platform prior to the ligation to part of processing unit of the platform, were also submitted to the registry.
Line 851: Line 851:
 
         </div>
 
         </div>
  
 +
        <h1 style="font-family: Rubik"> Formaldehyde <button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#formaldehyde" aria-expanded="false" aria-controls="formaldehyde" style="margin-left: 1%"></button></h1>
 +
        <div id="formaldehyde" class="collapse">
 +
 +
          <h2  style="font-size: 1em"> BioBricks used:</h2>
 +
 +
          <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
 +
          <p>
 +
          </p>
 +
 +
          <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Background Information </h2>
 +
          <p>
 +
          </p>
 +
 +
          <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Design Stage </h2>
 +
          <p>
 +
          </p>
 +
 +
          <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Implementation </h2>
 +
          <p>
 +
          </p>
 +
 +
          <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Conclusions and Future Work </h2>
 +
          <p>
 +
          </p>
 +
 +
          <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> References </h2>
 +
          <p>
 +
          </p>
 +
 +
        </div>
 
       </div>
 
       </div>
  
Line 866: Line 896:
  
  
       
+
 
 
           <h2  style="font-size: 1em"> BioBricks used: <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2205001">BBa_K2205001 (New)</a>, <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2205002">BBa_K2205002 (New)</a>, <a href="http://parts.igem.org/Part:BBa_K515105">BBa_K515105 (Imperial College London 2011)</a> </h2>
 
           <h2  style="font-size: 1em"> BioBricks used: <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2205001">BBa_K2205001 (New)</a>, <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2205002">BBa_K2205002 (New)</a>, <a href="http://parts.igem.org/Part:BBa_K515105">BBa_K515105 (Imperial College London 2011)</a> </h2>
       
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
 
           <p>deGFP is a variant of Green Fluorescent Protein (GFP). It was initially designed by Shin and Noireaux (2010) for expression in cell-free protein synthesis (CFPS) systems and is more efficiently translated than other variants (e.g. eGFP). Through talks with other biosensor developers (for example, Chris French), and after reviewing legislation regarding the use of synthetic biology outside of the lab environment, the importance of CFPS systems as a chassis was highlighted. Despite its importance, CFPS systems can still suffer from some issues such as lower total protein synthesis than whole cells. By standardising and characterising a GFP variant which has been modified to have enhanced expression in these systems, it is hoped that CFPS will become a more attractive option for researchers.
 
           <p>deGFP is a variant of Green Fluorescent Protein (GFP). It was initially designed by Shin and Noireaux (2010) for expression in cell-free protein synthesis (CFPS) systems and is more efficiently translated than other variants (e.g. eGFP). Through talks with other biosensor developers (for example, Chris French), and after reviewing legislation regarding the use of synthetic biology outside of the lab environment, the importance of CFPS systems as a chassis was highlighted. Despite its importance, CFPS systems can still suffer from some issues such as lower total protein synthesis than whole cells. By standardising and characterising a GFP variant which has been modified to have enhanced expression in these systems, it is hoped that CFPS will become a more attractive option for researchers.
Line 944: Line 974:
 
           <p>Text goes here.</p>
 
           <p>Text goes here.</p>
 
         </div>
 
         </div>
       
+
 
 
         <hr>
 
         <hr>
       
+
 
 
         <h1 style="font-family: Rubik"> Chromoproteins <button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#chromoproteins" aria-expanded="false" aria-controls="chromoproteins" style="margin-left: 1%"></button></h1>
 
         <h1 style="font-family: Rubik"> Chromoproteins <button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#chromoproteins" aria-expanded="false" aria-controls="chromoproteins" style="margin-left: 1%"></button></h1>
 
         <div id="chromoproteins" class="collapse">
 
         <div id="chromoproteins" class="collapse">
       
+
 
 
           <h2  style="font-size: 1em"> BioBricks used: <a href="http://parts.igem.org/Part:BBa_K2205016">BBa_K2205016(New)</a>,<a href="http://parts.igem.org/Part:BBa_K2205017">BBa_K2205017(New)</a>,<a href="http://parts.igem.org/Part:BBa_K2205018">BBa_K2205018(New)</a>, <a href="http://parts.igem.org/Part:BBa_K1033915">BBa_K1033915(Uppsala 2013)</a>, <a href="http://parts.igem.org/Part:BBa_K1033925">BBa_K1033925 (Uppsala 2013)</a>, <a href="http://parts.igem.org/Part:BBa_K1033929">BBa_K1033929 (Uppsala 2013)</a> </h2>
 
           <h2  style="font-size: 1em"> BioBricks used: <a href="http://parts.igem.org/Part:BBa_K2205016">BBa_K2205016(New)</a>,<a href="http://parts.igem.org/Part:BBa_K2205017">BBa_K2205017(New)</a>,<a href="http://parts.igem.org/Part:BBa_K2205018">BBa_K2205018(New)</a>, <a href="http://parts.igem.org/Part:BBa_K1033915">BBa_K1033915(Uppsala 2013)</a>, <a href="http://parts.igem.org/Part:BBa_K1033925">BBa_K1033925 (Uppsala 2013)</a>, <a href="http://parts.igem.org/Part:BBa_K1033929">BBa_K1033929 (Uppsala 2013)</a> </h2>
       
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
 
           <p>The Sensynova multicellular biosensor platform has been developed to overcome the <a href="https://2017.igem.org/Team:Newcastle/HP/Silver">limitations identified by our team</a> that hamper success in biosensor development. One of these limits regards the lack of modularity and reusability of the various components. Our platform design, based on the expression of three main modules (Detector, Processor and Reporter) by three <i>E.coli</i> strains in co-culture, allows the switch of possible variances for each module and the production of multiple customised biosensors.
 
           <p>The Sensynova multicellular biosensor platform has been developed to overcome the <a href="https://2017.igem.org/Team:Newcastle/HP/Silver">limitations identified by our team</a> that hamper success in biosensor development. One of these limits regards the lack of modularity and reusability of the various components. Our platform design, based on the expression of three main modules (Detector, Processor and Reporter) by three <i>E.coli</i> strains in co-culture, allows the switch of possible variances for each module and the production of multiple customised biosensors.
 
           </br></br>
 
           </br></br>
 
           This section of the project is based on testing the modularity of the system by replacing the sfGFP output part of the Sensynova platform design with three different output chromoprotein variants; BBa_K1033929 (aeBlue), BBa_K1033925 (spisPink) and BBa_K1033915 (amajLime).</p>
 
           This section of the project is based on testing the modularity of the system by replacing the sfGFP output part of the Sensynova platform design with three different output chromoprotein variants; BBa_K1033929 (aeBlue), BBa_K1033925 (spisPink) and BBa_K1033915 (amajLime).</p>
         
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Background Information </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Background Information </h2>
 
           <p>All three selected chromoproteins were made and submitted to the iGEM registry by the Uppsala 2013 team.
 
           <p>All three selected chromoproteins were made and submitted to the iGEM registry by the Uppsala 2013 team.
Line 968: Line 998:
 
           <p>The amajLime protein is a yellow-green chromoprotein extracted from the coral Anemonia majano. It was first extracted and characterized by Matz et al. under the name amFP486 (UniProtKB/Swiss-Prot: Q9U6Y6.1 GI: 56749103 GenBank: AF168421.1) and codon optimized for E coli by Genscript. The protein has an absorption maximum at 458 nm giving it a yellow-green colour visible to the naked eye.</p>
 
           <p>The amajLime protein is a yellow-green chromoprotein extracted from the coral Anemonia majano. It was first extracted and characterized by Matz et al. under the name amFP486 (UniProtKB/Swiss-Prot: Q9U6Y6.1 GI: 56749103 GenBank: AF168421.1) and codon optimized for E coli by Genscript. The protein has an absorption maximum at 458 nm giving it a yellow-green colour visible to the naked eye.</p>
 
           <img src="https://static.igem.org/mediawiki/2017/c/ca/T--Newcastle--Lais--amajLime.png" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 70%">
 
           <img src="https://static.igem.org/mediawiki/2017/c/ca/T--Newcastle--Lais--amajLime.png" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 70%">
         
+
 
 
           <h4 style="font-family: Rubik; text-align: left; margin-top: 1%">BBa_K1033925 – spisPink</h4>
 
           <h4 style="font-family: Rubik; text-align: left; margin-top: 1%">BBa_K1033925 – spisPink</h4>
 
           <p>The spisPink protein is a pink chromoprotein extracted from the coral Stylophora pistillata. It was first extracted and characterized by Alieva et al. under the name spisCP (GenBank: ABB17971.1) and codon optimized for E. coli by Genscript. The protein has an absorption maximum at 560 nm giving it a pink colour visible to the naked eye. The strong colour is readily observed in both LB or on agar plates after less than 24 hours of incubation.</p>
 
           <p>The spisPink protein is a pink chromoprotein extracted from the coral Stylophora pistillata. It was first extracted and characterized by Alieva et al. under the name spisCP (GenBank: ABB17971.1) and codon optimized for E. coli by Genscript. The protein has an absorption maximum at 560 nm giving it a pink colour visible to the naked eye. The strong colour is readily observed in both LB or on agar plates after less than 24 hours of incubation.</p>
 
           <img src="https://static.igem.org/mediawiki/2017/d/d9/T--Newcastle--Lais--Pink.png" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 70%">
 
           <img src="https://static.igem.org/mediawiki/2017/d/d9/T--Newcastle--Lais--Pink.png" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 70%">
         
+
 
 
           <h4 style="font-family: Rubik; text-align: left; margin-top: 1%">BBa_K1033929 – aeBlue</h4>
 
           <h4 style="font-family: Rubik; text-align: left; margin-top: 1%">BBa_K1033929 – aeBlue</h4>
 
           <p>The aeBlue protein is a blue chromoprotein extracted from the basal disk of a beadlet anemone Actinia equine. It was first extracted and characterized by Shkrob et al. 2005 under the name aeCP597 and codon optimised for E. coli by Bioneer Corp. The protein has an absorption maximum at 597nm and a deep blue colour visible to the naked eye. The protein aeBlue has significant sequence homologies with proteins in the GFP family. The coding sequence for this protein was originally submitted to the registry as BBa_K1033916 by the 2012 Uppsala iGEM team.</p>
 
           <p>The aeBlue protein is a blue chromoprotein extracted from the basal disk of a beadlet anemone Actinia equine. It was first extracted and characterized by Shkrob et al. 2005 under the name aeCP597 and codon optimised for E. coli by Bioneer Corp. The protein has an absorption maximum at 597nm and a deep blue colour visible to the naked eye. The protein aeBlue has significant sequence homologies with proteins in the GFP family. The coding sequence for this protein was originally submitted to the registry as BBa_K1033916 by the 2012 Uppsala iGEM team.</p>
 
           <img src="https://static.igem.org/mediawiki/2017/1/1c/T--Newcastle--Lais--Blue.png" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 70%">
 
           <img src="https://static.igem.org/mediawiki/2017/1/1c/T--Newcastle--Lais--Blue.png" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 70%">
         
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Design Stage </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Design Stage </h2>
 
           <p>In order to implement these three chromoprotein variants into the Sensynova platform, designs were made by replacing the sfGFP in the original reporter module with the parts detailed above that were ordered from the iGEM parts registry.</p>
 
           <p>In order to implement these three chromoprotein variants into the Sensynova platform, designs were made by replacing the sfGFP in the original reporter module with the parts detailed above that were ordered from the iGEM parts registry.</p>
 
           <img src="https://static.igem.org/mediawiki/2017/8/8a/T--Newcastle--Lais--Chromo--SBOL.png" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 70%">
 
           <img src="https://static.igem.org/mediawiki/2017/8/8a/T--Newcastle--Lais--Chromo--SBOL.png" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 70%">
         
+
 
 
<p>
 
<p>
 
  <h3><b>Figure 1:</b> <!--- Insert image name between tags. ---->
 
  <h3><b>Figure 1:</b> <!--- Insert image name between tags. ---->
 
<i> <b> SBOL Visual Detailing Reporter Variants</i> </b> </h3> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
 
<i> <b> SBOL Visual Detailing Reporter Variants</i> </b> </h3> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
</p></br>  
+
</p></br>
  
 
           <p>Using Benchling, virtual digestions of the three chromoproteins and ligations to the part K2205013, the connector 2 receiver module detailed above, were carried out resulting in the three plasmid maps detailed below; parts K2205016, K2205017 and K220518.</p>
 
           <p>Using Benchling, virtual digestions of the three chromoproteins and ligations to the part K2205013, the connector 2 receiver module detailed above, were carried out resulting in the three plasmid maps detailed below; parts K2205016, K2205017 and K220518.</p>
  
         
+
 
 
           <a target="_blank" href="https://static.igem.org/mediawiki/2017/3/36/T--Newcastle--Lais--Chromo--Lime--Map.png">
 
           <a target="_blank" href="https://static.igem.org/mediawiki/2017/3/36/T--Newcastle--Lais--Chromo--Lime--Map.png">
 
           <img src="https://static.igem.org/mediawiki/2017/3/36/T--Newcastle--Lais--Chromo--Lime--Map.png" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 30%">
 
           <img src="https://static.igem.org/mediawiki/2017/3/36/T--Newcastle--Lais--Chromo--Lime--Map.png" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 30%">
Line 1,001: Line 1,031:
 
  <h3><b>Figure 2, 3, and 4:</b> <!--- Insert image name between tags. ---->
 
  <h3><b>Figure 2, 3, and 4:</b> <!--- Insert image name between tags. ---->
 
<i> <b> Parts<a href="http://parts.igem.org/Part:BBa_K2205016"> BBa_K2205016</a>, <a href="http://parts.igem.org/Part:BBa_K2205017"> BBa_K2205017</a> and <a href="http://parts.igem.org/Part:BBa_K2205018"> BBa_K2205018</a> in PSB1C3</i> (Click for larger images) </b> </h3> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
 
<i> <b> Parts<a href="http://parts.igem.org/Part:BBa_K2205016"> BBa_K2205016</a>, <a href="http://parts.igem.org/Part:BBa_K2205017"> BBa_K2205017</a> and <a href="http://parts.igem.org/Part:BBa_K2205018"> BBa_K2205018</a> in PSB1C3</i> (Click for larger images) </b> </h3> <!--- Described what the diagram is showing. If biobricks are depicted give BBa_ numbers -->
</p></br>  
+
</p></br>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Implementation </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Implementation </h2>
 
           <p>The chromoproteins aeBlue (BBa_K1033929), amajLime (BBa_K1033915) and spisPink (BBa_K1033925) parts were requested from the iGEM parts registry. Upon arrival, parts were transformed in DH5α E. coli cells [Protocol link]. Colonies were picked and overnight cultures were prepared for miniprepping [Protocol link]. Minipreps were digested [Protocol link] with XbaI and PstI for BioBrick assembly [Protocol link].
 
           <p>The chromoproteins aeBlue (BBa_K1033929), amajLime (BBa_K1033915) and spisPink (BBa_K1033925) parts were requested from the iGEM parts registry. Upon arrival, parts were transformed in DH5α E. coli cells [Protocol link]. Colonies were picked and overnight cultures were prepared for miniprepping [Protocol link]. Minipreps were digested [Protocol link] with XbaI and PstI for BioBrick assembly [Protocol link].
Line 1,016: Line 1,046:
 
           </br></br>
 
           </br></br>
 
           <img src="PIC HERE LAIS" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 70%">
 
           <img src="PIC HERE LAIS" class="img-fluid border border-dark rounded" style="margin: 2%; max-width: 70%">
         
+
 
 
<p>
 
<p>
 
  <h3><b>Figure 5:</b> <!--- Insert image name between tags. ---->
 
  <h3><b>Figure 5:</b> <!--- Insert image name between tags. ---->
Line 1,023: Line 1,053:
 
<p>
 
<p>
 
           </br></br>
 
           </br></br>
There is a visible vibrant colour change present for both the spisPink and the aeBlue chromoprotein variants however, as the colour of the amajLime is very similar to the wildtype colour, both in cultures, pelleted and plated, the colour is difficulty distinguished. For this reason, it was decided to carry forward the two brightest chromoproteins for further testing while optimising amajLime separately.
+
There is a visible vibrant colour change present for both the spisPink and the aeBlue chromoprotein variants however, as the colour of the amajLime is very similar to the wildtype colour, both in cultures, pelleted and plated, the colour is difficulty distinguished. For this reason, it was decided to carry forward the two brightest chromoproteins for further testing while optimising amajLime separately.
 
           </br></br>
 
           </br></br>
</b>In order to test these two chromoproteins reporter variants into the Sensynova framework, cultures of IPTG detector, processor unit and three reporter modules, two chromopreteins and the sfGFP control, were inoculated and grown overnight in LB+chloramphenicol (12,5ng/μl).  
+
</b>In order to test these two chromoproteins reporter variants into the Sensynova framework, cultures of IPTG detector, processor unit and three reporter modules, two chromopreteins and the sfGFP control, were inoculated and grown overnight in LB+chloramphenicol (12,5ng/μl).
 
           </br></br>
 
           </br></br>
The cultures were then diluted at OD600: 0,1 and mixed together to obtain co-cultures with ratio 1:1:1 and 1:1:13. Some samples were supplemented with 1mM IPTG to induce the expression of quorum sensing molecules and eventually achieve the chromoproteins visualisation (Figures 6, 7, 8).  
+
The cultures were then diluted at OD600: 0,1 and mixed together to obtain co-cultures with ratio 1:1:1 and 1:1:13. Some samples were supplemented with 1mM IPTG to induce the expression of quorum sensing molecules and eventually achieve the chromoproteins visualisation (Figures 6, 7, 8).
 
</p>
 
</p>
  
</p>  
+
</p>
 
<table class="image_table" style="background:none">
 
<table class="image_table" style="background:none">
 
<tr>
 
<tr>
Line 1,063: Line 1,093:
 
</tr>
 
</tr>
 
</table>
 
</table>
<p>The three experiment sets clearly demonstrate that the framework is optimised when a higher concentration of cells expressing the reporter device is present (Figures 6, 7, 8, samples labelled 1:1:13).  
+
<p>The three experiment sets clearly demonstrate that the framework is optimised when a higher concentration of cells expressing the reporter device is present (Figures 6, 7, 8, samples labelled 1:1:13).
 
           </br></br>
 
           </br></br>
Although a background signal is visible in the systems expressing the pink (<a href="http://parts.igem.org/Part:BBa_K2205018">BBa_K2205018</a>) and the sfGPF (<a href="http://parts.igem.org/Part:BBa_K2205015">BBa_K2205015</a>) reporters, the blue reporter (<a href="http://parts.igem.org/Part:BBa_K2205016">BBa_K2205016</a>) due to its lowest background level, constitutes the most suitable reporter module for the Sensynova platform when customised as IPTG biosensor.  
+
Although a background signal is visible in the systems expressing the pink (<a href="http://parts.igem.org/Part:BBa_K2205018">BBa_K2205018</a>) and the sfGPF (<a href="http://parts.igem.org/Part:BBa_K2205015">BBa_K2205015</a>) reporters, the blue reporter (<a href="http://parts.igem.org/Part:BBa_K2205016">BBa_K2205016</a>) due to its lowest background level, constitutes the most suitable reporter module for the Sensynova platform when customised as IPTG biosensor.
 
  </p>
 
  </p>
  
Line 1,085: Line 1,115:
 
           Shkrob, M., Yanushevich, Y., Chudakov, D., Gurskaya, N., Labas, Y., Poponov, S., Mudrik, N., Lukyanov, S. and Lukyanov, K. (2005). Far-red fluorescent proteins evolved from a blue chromoprotein fromActinia equina. Biochemical Journal, 392(3), pp.649-654.</p>
 
           Shkrob, M., Yanushevich, Y., Chudakov, D., Gurskaya, N., Labas, Y., Poponov, S., Mudrik, N., Lukyanov, S. and Lukyanov, K. (2005). Far-red fluorescent proteins evolved from a blue chromoprotein fromActinia equina. Biochemical Journal, 392(3), pp.649-654.</p>
 
         </div>
 
         </div>
       
+
 
 
       </div>
 
       </div>
  
Line 1,092: Line 1,122:
 
         <h1 style="font-family: Rubik"> Sensynova Framework Testing <span style="font-family: Arial">(</span>IPTG Sensor<span style="font-family: Arial">)</span>: The Results <!--<button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#framework" aria-expanded="false" aria-controls="framework" style="margin-left: 1%"></button>--></h1>
 
         <h1 style="font-family: Rubik"> Sensynova Framework Testing <span style="font-family: Arial">(</span>IPTG Sensor<span style="font-family: Arial">)</span>: The Results <!--<button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#framework" aria-expanded="false" aria-controls="framework" style="margin-left: 1%"></button>--></h1>
 
         <div id="framework">
 
         <div id="framework">
       
+
 
 
           <h2  style="font-size: 1em"> BioBricks used: <a href="http://parts.igem.org/Part:BBa_K2205009">BBa_K2205009(New)</a>, <a href="http://parts.igem.org/Part:BBa_K2205012">BBa_K2205012(New)</a>, <a href="http://parts.igem.org/Part:BBa_K2205015">BBa_K2205015(New)</a>, <a href="http://parts.igem.org/Part:BBa_K2205016">BBa_K2205016(New)</a> and <a href="http://parts.igem.org/Part:BBa_K2205018">BBa_K2205018(New)</a>.
 
           <h2  style="font-size: 1em"> BioBricks used: <a href="http://parts.igem.org/Part:BBa_K2205009">BBa_K2205009(New)</a>, <a href="http://parts.igem.org/Part:BBa_K2205012">BBa_K2205012(New)</a>, <a href="http://parts.igem.org/Part:BBa_K2205015">BBa_K2205015(New)</a>, <a href="http://parts.igem.org/Part:BBa_K2205016">BBa_K2205016(New)</a> and <a href="http://parts.igem.org/Part:BBa_K2205018">BBa_K2205018(New)</a>.
  
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
 
           <p>Motivation: Biosensors, synthetic systems designed to detect and respond to a target analyte, are a common application of synthetic biology. However, the production and screening of multiple biosensor system variants is hindered by the inefficiency and specificity of the gene assembly techniques used. The production of circuit variants is important in biosensor production, as sensitivity to target molecules must be tuned. Aim: To develop a multicellular biosensor development platform which utilises cell-mixing, as opposed to genetic re-engineering, to construct biosensor variants.</p>
 
           <p>Motivation: Biosensors, synthetic systems designed to detect and respond to a target analyte, are a common application of synthetic biology. However, the production and screening of multiple biosensor system variants is hindered by the inefficiency and specificity of the gene assembly techniques used. The production of circuit variants is important in biosensor production, as sensitivity to target molecules must be tuned. Aim: To develop a multicellular biosensor development platform which utilises cell-mixing, as opposed to genetic re-engineering, to construct biosensor variants.</p>
         
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Background Information </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Background Information </h2>
 
           <p><b>Human Practices Quotes: </b></p>
 
           <p><b>Human Practices Quotes: </b></p>
Line 1,119: Line 1,149:
 
           </br></br>
 
           </br></br>
  
<img src="https://static.igem.org/mediawiki/2017/6/63/Framework_generic.jpg"img-fluid border border-dark rounded"
+
<img src="https://static.igem.org/mediawiki/2017/6/63/Framework_generic.jpg" class="img-fluid rounded mx-auto d-block" style="max-width: 60%" alt="">
class="img-fluid rounded mx-auto d-block" style="max-width: 60%" alt="">
+
 
<p>
 
<p>
<b>Figure 2:</b> Modular and multicellular Sensynova framework design.  
+
<b>Figure 2:</b> Modular and multicellular Sensynova framework design.
 
</br></br></p>
 
</br></br></p>
 
         <p> The splitting of biosensor components into separate cells may have additional advantages besides ease of variant production. Goni-Moreno et al. (2011) have previously suggested that the use of synthetic quorum sensing circuits enables each cell to be considered an independent logic gate, which may rectify the “fuzzy logic” seen in some biosensors, where stochastic cellular processes may produce false positive results. Quorum sensing has also been previously used to synchronise gene expressions, leading to reduced variability within a population (Danino et al., 2010).</p>
 
         <p> The splitting of biosensor components into separate cells may have additional advantages besides ease of variant production. Goni-Moreno et al. (2011) have previously suggested that the use of synthetic quorum sensing circuits enables each cell to be considered an independent logic gate, which may rectify the “fuzzy logic” seen in some biosensors, where stochastic cellular processes may produce false positive results. Quorum sensing has also been previously used to synchronise gene expressions, leading to reduced variability within a population (Danino et al., 2010).</p>
Line 1,130: Line 1,159:
  
 
           <p>In order to support our theory that genetic assembly is the rate limiting step in biosensor development, we attempted to assemble a simple GFP producing system using three engineering techniques: BioBrick, Gibson and Golden Gate. Further information about this experiment can be found on our <a href="https://2017.igem.org/Team:Newcastle/InterLab">interlab page</a> . Gibson was the only successful technique we trailed, however, Gibson assembly is not an ideal method for circuit variant production due the the specificity of the overlapping regions: For example, to assemble ten genetic parts into all possible orders would require the use of 90 different overlapping sequences (Ellis et al., 2011). Therefore, the ability to generate circuit variants without the need for further genetic engineering would be useful.</p>
 
           <p>In order to support our theory that genetic assembly is the rate limiting step in biosensor development, we attempted to assemble a simple GFP producing system using three engineering techniques: BioBrick, Gibson and Golden Gate. Further information about this experiment can be found on our <a href="https://2017.igem.org/Team:Newcastle/InterLab">interlab page</a> . Gibson was the only successful technique we trailed, however, Gibson assembly is not an ideal method for circuit variant production due the the specificity of the overlapping regions: For example, to assemble ten genetic parts into all possible orders would require the use of 90 different overlapping sequences (Ellis et al., 2011). Therefore, the ability to generate circuit variants without the need for further genetic engineering would be useful.</p>
         
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Design Stage </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Design Stage </h2>
 
           <p>To modularise biosensor components, it was necessary to first confirm which devices types are commonly found in biosensors. An in depth systematic review was conducted to determine these components. Team seeker, a tool for keyword searches of iGEM team titles and abstracts for the years 2008 to 2016, was used to identify biosensor based projects (Aalto-Helsinki iGEM team, 2014). The search terms used to identify potentially relevant projects were “sense” and “biosensor”. 121 projects were identified by these search terms. In projects including multiple sensors, the most well characterised sensors were used for this review. Sensor designs, rather than constructed biosensors, were used for analysis, as time constraints in iGEM often prevents project completion.
 
           <p>To modularise biosensor components, it was necessary to first confirm which devices types are commonly found in biosensors. An in depth systematic review was conducted to determine these components. Team seeker, a tool for keyword searches of iGEM team titles and abstracts for the years 2008 to 2016, was used to identify biosensor based projects (Aalto-Helsinki iGEM team, 2014). The search terms used to identify potentially relevant projects were “sense” and “biosensor”. 121 projects were identified by these search terms. In projects including multiple sensors, the most well characterised sensors were used for this review. Sensor designs, rather than constructed biosensors, were used for analysis, as time constraints in iGEM often prevents project completion.
 
           </br></br>
 
           </br></br>
           Ten projects were unable to be reviewed because their wiki was broken. Of the remaining 111 projects, 18 projects were deemed not eligible for further analysis. This was either due to a lack of information regarding biosensor mechanism provided by the team or their project was irrelevant. 3 projects were excluded as the sensing component of their project was unchanged from a previous project, to prevent the overrepresentation of biosensors in our database. Therefore, a total of 93 biosensors were used for analysis in our systematic review (Figure 3 and table 1). </br></br>The systematic review revealed that all biosensors could be split into four components:  
+
           Ten projects were unable to be reviewed because their wiki was broken. Of the remaining 111 projects, 18 projects were deemed not eligible for further analysis. This was either due to a lack of information regarding biosensor mechanism provided by the team or their project was irrelevant. 3 projects were excluded as the sensing component of their project was unchanged from a previous project, to prevent the overrepresentation of biosensors in our database. Therefore, a total of 93 biosensors were used for analysis in our systematic review (Figure 3 and table 1). </br></br>The systematic review revealed that all biosensors could be split into four components:
 
</br>
 
</br>
 
       <b> 1)Detector: </b>The part responsible for detection of the target molecules. For example, riboswitches and transcription factors. </br>
 
       <b> 1)Detector: </b>The part responsible for detection of the target molecules. For example, riboswitches and transcription factors. </br>
 
       <b> 2)Processing: </b>Adds downstream processing to a signal, which enables response turning. For example, logic gates, signal amplification and sensitivity tuning. </br>
 
       <b> 2)Processing: </b>Adds downstream processing to a signal, which enables response turning. For example, logic gates, signal amplification and sensitivity tuning. </br>
 
       <b>3)Reporter or output: </b>Produces a response to the target. For example, fluorescent proteins and beta-galactosidase. Additionally, some biosensors may produce outputs which interact with the target molecule once it has been sensed, such as the production of degradation enzymes in bioremediation projects. We have termed these outputs as “effectors”.</br>
 
       <b>3)Reporter or output: </b>Produces a response to the target. For example, fluorescent proteins and beta-galactosidase. Additionally, some biosensors may produce outputs which interact with the target molecule once it has been sensed, such as the production of degradation enzymes in bioremediation projects. We have termed these outputs as “effectors”.</br>
<b>4)Adaptors: </b> If the molecule is hard to detect, adaptor components can be placed before the detector unit, to convert the target molecules to something able to be sensed by the detector component. For example, for target that degrades into an easily detectable molecule, a biochemical conversion adaptor could be placed before the detector component which enzymatically degrades the target molecule into the molecule detected by the detector module.  
+
<b>4)Adaptors: </b> If the molecule is hard to detect, adaptor components can be placed before the detector unit, to convert the target molecules to something able to be sensed by the detector component. For example, for target that degrades into an easily detectable molecule, a biochemical conversion adaptor could be placed before the detector component which enzymatically degrades the target molecule into the molecule detected by the detector module.
 
           </br></br></br>
 
           </br></br></br>
 
<img class="mySlides" src="https://static.igem.org/mediawiki/2017/f/f6/T--Newcastle--BB_Design-0.png" width="100%">
 
<img class="mySlides" src="https://static.igem.org/mediawiki/2017/f/f6/T--Newcastle--BB_Design-0.png" width="100%">
Line 1,150: Line 1,179:
 
<b>Table 1: </b>Percentages of biosensors components used in iGEM. </p>
 
<b>Table 1: </b>Percentages of biosensors components used in iGEM. </p>
 
</br></br>
 
</br></br>
       
+
 
 
         <p> We propose that splitting these modular biosensor components into different cells, as shown below, and co-culturing the cells together, will greatly reduce the complexity of biosensor circuit development. </p>
 
         <p> We propose that splitting these modular biosensor components into different cells, as shown below, and co-culturing the cells together, will greatly reduce the complexity of biosensor circuit development. </p>
  
Line 1,158: Line 1,187:
 
<img src="https://static.igem.org/mediawiki/2017/5/5c/Iptg_framework.jpg" class="img-fluid rounded mx-auto d-block" style="max-width: 60%" alt="">
 
<img src="https://static.igem.org/mediawiki/2017/5/5c/Iptg_framework.jpg" class="img-fluid rounded mx-auto d-block" style="max-width: 60%" alt="">
 
<p>
 
<p>
<b>Figure 4: Sensynova framework design used for sensing IPTG. </b></p>  
+
<b>Figure 4: Sensynova framework design used for sensing IPTG. </b></p>
  
 
           </br></br>
 
           </br></br>
Line 1,165: Line 1,194:
 
<img src="https://static.igem.org/mediawiki/2017/1/10/Framework_gel_parts.png" class="img-fluid rounded mx-auto d-block" style="max-width: 60%" alt="">
 
<img src="https://static.igem.org/mediawiki/2017/1/10/Framework_gel_parts.png" class="img-fluid rounded mx-auto d-block" style="max-width: 60%" alt="">
 
<p>
 
<p>
<b>Figure 5:</b> Colony PCR confirming the correct integration of the biosensor fragments into the vector. </p>  
+
<b>Figure 5:</b> Colony PCR confirming the correct integration of the biosensor fragments into the vector. </p>
  
  
Line 1,183: Line 1,212:
  
 
<p>
 
<p>
  <b>Figure 6: </b> The reporter part <a href="http://parts.igem.org/Part:BBa_K2205015">BBa_K2205015</a> test shows a significant fluorescence increase after induction with the connecting molecule 2 C12-RHL.  
+
  <b>Figure 6: </b> The reporter part <a href="http://parts.igem.org/Part:BBa_K2205015">BBa_K2205015</a> test shows a significant fluorescence increase after induction with the connecting molecule 2 C12-RHL.
+
 
 
</p> </br>
 
</p> </br>
  
Line 1,206: Line 1,235:
 
<img src="https://static.igem.org/mediawiki/2017/1/10/Framework_test_111.jpg" class="img-fluid rounded mx-auto d-block" style="max-width: 60%" alt="">
 
<img src="https://static.igem.org/mediawiki/2017/1/10/Framework_test_111.jpg" class="img-fluid rounded mx-auto d-block" style="max-width: 60%" alt="">
 
</p>
 
</p>
<p> <b>Figure 8:</b> Framework (<a href="http://parts.igem.org/Part:BBa_K2205009">BBa_K2205009</a> , <a href="http://parts.igem.org/Part:BBa_K2205012">BBa_K2205012</a> , <a href="http://parts.igem.org/Part:BBa_K2205015">BBa_K2205015</a> ) test with a co-culture in ratio 1:1:1 in response of IPTG induction.  
+
<p> <b>Figure 8:</b> Framework (<a href="http://parts.igem.org/Part:BBa_K2205009">BBa_K2205009</a> , <a href="http://parts.igem.org/Part:BBa_K2205012">BBa_K2205012</a> , <a href="http://parts.igem.org/Part:BBa_K2205015">BBa_K2205015</a> ) test with a co-culture in ratio 1:1:1 in response of IPTG induction.
 
</p> </br>
 
</p> </br>
 
<p>
 
<p>
Line 1,219: Line 1,248:
 
<p>
 
<p>
 
<p class="legend"><strong><b>Figure 9:</b></strong> Framework (<a href="http://parts.igem.org/Part:BBa_K2205009">BBa_K2205009</a> , <a href="http://parts.igem.org/Part:BBa_K2205012">BBa_K2205012</a> , <a href="http://parts.igem.org/Part:BBa_K2205015">BBa_K2205015</a> )  test with a co-culture in ratio 1:1:13 in response of IPTG induction.
 
<p class="legend"><strong><b>Figure 9:</b></strong> Framework (<a href="http://parts.igem.org/Part:BBa_K2205009">BBa_K2205009</a> , <a href="http://parts.igem.org/Part:BBa_K2205012">BBa_K2205012</a> , <a href="http://parts.igem.org/Part:BBa_K2205015">BBa_K2205015</a> )  test with a co-culture in ratio 1:1:13 in response of IPTG induction.
</p>  
+
</p>
 
<p>
 
<p>
The experimental data validate the model prediction showing that the system worked most optimally when the reporter cells were in excess of both the detector and processor cells. One of the reasons that this configuration was the best may be because of signal amplification at each of the quorum sensing communication stages. The quorum sensing mechanism used here is the acyl homoserine lactone (AHL) system in gram negative bacteria. This system works by one cell producing a quorum sensing molecule which can diffuse out through its membrane. Once the extracellular space reaches a certain threshold concentration of AHL molecule, the AHL will begin to diffuse into other cells in the community. If the cell the AHL molecule enters has the appropriate transcription factor present (e.g. LasR for the C12 AHL), then transcription of a gene under the control of the pLas promoter can occur. Therefore, if background expression of the AHL is high enough to reach above the threshold level, then expression of the next quorum sensing molecule in another cell (in this case C4 AHL) will occur. By reducing the amount of detector and processor cells present in the system, the background expression levels of C12 and C4 will be lower, and hence expression of sfGFP by the reporter cell will be lower.  
+
The experimental data validate the model prediction showing that the system worked most optimally when the reporter cells were in excess of both the detector and processor cells. One of the reasons that this configuration was the best may be because of signal amplification at each of the quorum sensing communication stages. The quorum sensing mechanism used here is the acyl homoserine lactone (AHL) system in gram negative bacteria. This system works by one cell producing a quorum sensing molecule which can diffuse out through its membrane. Once the extracellular space reaches a certain threshold concentration of AHL molecule, the AHL will begin to diffuse into other cells in the community. If the cell the AHL molecule enters has the appropriate transcription factor present (e.g. LasR for the C12 AHL), then transcription of a gene under the control of the pLas promoter can occur. Therefore, if background expression of the AHL is high enough to reach above the threshold level, then expression of the next quorum sensing molecule in another cell (in this case C4 AHL) will occur. By reducing the amount of detector and processor cells present in the system, the background expression levels of C12 and C4 will be lower, and hence expression of sfGFP by the reporter cell will be lower.
 
<p>
 
<p>
 
</p> </br>
 
</p> </br>
<p><b> Qualitative test with chromoproteins expression. </b>In order to check the performance of the Sensynova device in terms of modularity, cultures of IPTG detector, processor unit and 3 different reporter modules carrying 2 chromoproteins (Chromoproteins link)(<a href="http://parts.igem.org/Part:BBa_K2205016">BBa_K2205016</a>, <a href="http://parts.igem.org/Part:BBa_K2205018">BBa_K2205018</a>)and sfGFP(<a href="http://parts.igem.org/Part:BBa_K2205015">BBa_K2205015</a>) were inoculated and grown overnight in LB+chloramphenicol(12,5ng/ul). The day after the cultures were diluted at OD600: 0,1 and mixed together to obtain co-cultures with ratio 1:1:1 and 1:1:13. Some samples were supplemented with 1mM IPTG to induce the expression of quorum sensing molecules and eventually achieve the chromoproteins visualisation (Figures 10, 11, 12).  
+
<p><b> Qualitative test with chromoproteins expression. </b>In order to check the performance of the Sensynova device in terms of modularity, cultures of IPTG detector, processor unit and 3 different reporter modules carrying 2 chromoproteins (Chromoproteins link)(<a href="http://parts.igem.org/Part:BBa_K2205016">BBa_K2205016</a>, <a href="http://parts.igem.org/Part:BBa_K2205018">BBa_K2205018</a>)and sfGFP(<a href="http://parts.igem.org/Part:BBa_K2205015">BBa_K2205015</a>) were inoculated and grown overnight in LB+chloramphenicol(12,5ng/ul). The day after the cultures were diluted at OD600: 0,1 and mixed together to obtain co-cultures with ratio 1:1:1 and 1:1:13. Some samples were supplemented with 1mM IPTG to induce the expression of quorum sensing molecules and eventually achieve the chromoproteins visualisation (Figures 10, 11, 12).
  
  
</p>  
+
</p>
 
<table class="image_table" style="background:none">
 
<table class="image_table" style="background:none">
 
<tr>
 
<tr>
Line 1,271: Line 1,300:
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> The next step </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> The next step </h2>
 
           <p>Another advantage to the bypassing of gene assembly enabled by our platform is the increased ability to automate system construction. Microfludic systems are those which control the movement of small volumes of liquids (10–9 to 10–18 litres) using a variety of methods, which may be used to perform biological experiments. These devices have a number of advantages over traditional, manual, lab methods. They only use a small amount of liquid, which means less reagents are consumed and the time taken to perform experiments is reduced. These small amounts of liquids are easier to manipulate than larger volumes, meaning there is greater control over reactions resulting in a high degree of sensitivity (Whitesides, 2006). However, many devices do not have the ability to control temperature, which is important for many methods of gene assembly. Cell mixing, as opposed to gene fragment assembly, is more suited to automation on these platforms, as there is no requirement for precise temperature control. Also, the increased control over small volumes of reagents allows the screening of precise cell ratios. Additionally, programs are in development for the automation of protocols on microfluidic, which will allow the rapid combination of a number of variant biosensor components. To utilise this advantage, we conducted a number of experiments using liquid handling robots (LINK TO ROBOTICS PAGE) and developed <a href="https://2017.igem.org/Team:Newcastle/Model#mf ">software</a> for the simulation of microfludics experiments </p>
 
           <p>Another advantage to the bypassing of gene assembly enabled by our platform is the increased ability to automate system construction. Microfludic systems are those which control the movement of small volumes of liquids (10–9 to 10–18 litres) using a variety of methods, which may be used to perform biological experiments. These devices have a number of advantages over traditional, manual, lab methods. They only use a small amount of liquid, which means less reagents are consumed and the time taken to perform experiments is reduced. These small amounts of liquids are easier to manipulate than larger volumes, meaning there is greater control over reactions resulting in a high degree of sensitivity (Whitesides, 2006). However, many devices do not have the ability to control temperature, which is important for many methods of gene assembly. Cell mixing, as opposed to gene fragment assembly, is more suited to automation on these platforms, as there is no requirement for precise temperature control. Also, the increased control over small volumes of reagents allows the screening of precise cell ratios. Additionally, programs are in development for the automation of protocols on microfluidic, which will allow the rapid combination of a number of variant biosensor components. To utilise this advantage, we conducted a number of experiments using liquid handling robots (LINK TO ROBOTICS PAGE) and developed <a href="https://2017.igem.org/Team:Newcastle/Model#mf ">software</a> for the simulation of microfludics experiments </p>
       
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> References </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> References </h2>
 
           <p>Aalto-Helsinki iGEM team (2014) Team Seeker [online] Available at: http://igem-qsf.github.io/iGEM-Team-Seeker/dist/ [Accessed 11/07/17]
 
           <p>Aalto-Helsinki iGEM team (2014) Team Seeker [online] Available at: http://igem-qsf.github.io/iGEM-Team-Seeker/dist/ [Accessed 11/07/17]
Line 1,304: Line 1,333:
 
         <h1 style="font-family: Rubik"> Cell Free Protein Synthesis System Optimisation: The Results <!--<button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#cellfree" aria-expanded="false" aria-controls="cellfree" style="margin-left: 1%"></button>--></h1>
 
         <h1 style="font-family: Rubik"> Cell Free Protein Synthesis System Optimisation: The Results <!--<button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#cellfree" aria-expanded="false" aria-controls="cellfree" style="margin-left: 1%"></button>--></h1>
 
         <div id="cellfree">
 
         <div id="cellfree">
       
+
 
 
           <h2  style="font-size: 1em"> BioBricks used: <a href="http://parts.igem.org/Part:BBa_K515105">BBa_K515105 (Imperial College London 2011)</a> </h2>
 
           <h2  style="font-size: 1em"> BioBricks used: <a href="http://parts.igem.org/Part:BBa_K515105">BBa_K515105 (Imperial College London 2011)</a> </h2>
  
Line 1,312: Line 1,341:
 
<p class="legend"><strong>Cell Free Protein Synthesis Premix Supplements:</strong> Diagrammatic overview of CFPS supplement roles in transcription and translation.</p>
 
<p class="legend"><strong>Cell Free Protein Synthesis Premix Supplements:</strong> Diagrammatic overview of CFPS supplement roles in transcription and translation.</p>
 
</div>
 
</div>
       
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Rationale and Aim </h2>
 
           <p>Cell free protein synthesis (CFPS) systems have large potential as alternative chassis for applications such biosensors or diagnostic tests. This is because generally, biosensors are needed to function outside of the laboratory environment. Whole cells, which are traditionally used as chassis, can be problematic in these scenarios due to issues with containment and release of genetically modified organisms.
 
           <p>Cell free protein synthesis (CFPS) systems have large potential as alternative chassis for applications such biosensors or diagnostic tests. This is because generally, biosensors are needed to function outside of the laboratory environment. Whole cells, which are traditionally used as chassis, can be problematic in these scenarios due to issues with containment and release of genetically modified organisms.
Line 1,320: Line 1,349:
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Background Information </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Background Information </h2>
 
           <h4 style="font-family: Rubik; text-align: left; margin-top: 1%"> Cell Free Protein Synthesis Systems </h4>
 
           <h4 style="font-family: Rubik; text-align: left; margin-top: 1%"> Cell Free Protein Synthesis Systems </h4>
           <p>Cell free protein synthesis (CFPS) systems are capable of performing transcription and translation of exogenous DNA in vitro. CFPS systems have been in use for many decades (Nirenberg & Matthaei, 1961), however the field of synthetic biology has resulted in a CFPS renaissance (Lu, 2017; Lee & Kim, 2013). Commonly, CFPS systems are based on cell extracts, which provide the transcription/translation machinery, as well as enzymes required to generate ATP required for protein synthesis.  
+
           <p>Cell free protein synthesis (CFPS) systems are capable of performing transcription and translation of exogenous DNA in vitro. CFPS systems have been in use for many decades (Nirenberg & Matthaei, 1961), however the field of synthetic biology has resulted in a CFPS renaissance (Lu, 2017; Lee & Kim, 2013). Commonly, CFPS systems are based on cell extracts, which provide the transcription/translation machinery, as well as enzymes required to generate ATP required for protein synthesis.
 
           </br></br>
 
           </br></br>
 
           While CFPS systems have a lot of potential, they also suffer from some drawbacks. Two of the major issues are the large variation in CFPS activity between cell extracts (Katsura, et al., 2017), and the high costs compared to whole cells (although cost have been reduced significantly in the past decade) (Carlson, et al., 2012). These issues can hinder the uptake of CFPS systems as an alternative chassis to whole cells, and as research tools.</p>
 
           While CFPS systems have a lot of potential, they also suffer from some drawbacks. Two of the major issues are the large variation in CFPS activity between cell extracts (Katsura, et al., 2017), and the high costs compared to whole cells (although cost have been reduced significantly in the past decade) (Carlson, et al., 2012). These issues can hinder the uptake of CFPS systems as an alternative chassis to whole cells, and as research tools.</p>
Line 1,326: Line 1,355:
 
           <p>Show/hide more information about the CFPS premix <button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#cfps" aria-expanded="false" aria-controls="cfps" style="margin-left: 1%"></button></p>
 
           <p>Show/hide more information about the CFPS premix <button class="btn btn-primary collapsed" type="button" data-toggle="collapse" data-target="#cfps" aria-expanded="false" aria-controls="cfps" style="margin-left: 1%"></button></p>
 
           <div id="cfps" class="collapse" style="border: 1px solid #222222; padding: 1%">
 
           <div id="cfps" class="collapse" style="border: 1px solid #222222; padding: 1%">
         
+
 
             <p>Cells extracts being used in CFPS systems tend to be supplemented with a cocktail of compounds and molecules to aid the process of transcription and translation. Although exact supplement solutions can vary from protocol to protocol, most have the same basic composition; salts, nucleotides, tRNAs, co-factors, energy sources, and amino acids (Yang, et al., 2012). The supplement solution used in this study is based on the Cytomin system (figure 1.2.1) (Jewett, et al., 2008). For the cytomin supplement solution, the major energy source is sodium pyruvate, which is converted to acetate through a series of reactions catalysed by enzymes in the crude cell extract (Figure 1.2.2). The first reaction, pyruvate to acetyl-CoA, requires nicotinamide diphosphate (NAD) and Co-enzyme A (CoA) as co-factors. Both of these are components of the premix and hence added to the system to enhance flux through the reaction. The acetyl CoA is phosphorylated by inorganic phosphate, and then de-phosphorylated to produce ATP from ADP. The ATP is used as energy to drive translation of mRNA.  
+
             <p>Cells extracts being used in CFPS systems tend to be supplemented with a cocktail of compounds and molecules to aid the process of transcription and translation. Although exact supplement solutions can vary from protocol to protocol, most have the same basic composition; salts, nucleotides, tRNAs, co-factors, energy sources, and amino acids (Yang, et al., 2012). The supplement solution used in this study is based on the Cytomin system (figure 1.2.1) (Jewett, et al., 2008). For the cytomin supplement solution, the major energy source is sodium pyruvate, which is converted to acetate through a series of reactions catalysed by enzymes in the crude cell extract (Figure 1.2.2). The first reaction, pyruvate to acetyl-CoA, requires nicotinamide diphosphate (NAD) and Co-enzyme A (CoA) as co-factors. Both of these are components of the premix and hence added to the system to enhance flux through the reaction. The acetyl CoA is phosphorylated by inorganic phosphate, and then de-phosphorylated to produce ATP from ADP. The ATP is used as energy to drive translation of mRNA.
 
             </br></br>
 
             </br></br>
             Energy can also be derived from glutamate in the supplement solution (Jewett, et al., 2008), which is added in the form of magnesium glutamate and potassium glutamate. Glutamate is a metabolite in the tricarboxylic acid cycle, which generates NADH. In whole cells, NADH is used in oxidative phosphorylation to produce ATP. Oxidative phosphorylation relies on membrane bound proteins and proton gradients across a membrane. It has been shown previously that extracts prepared using French Press or sonication contain membrane vesicles which have ATPase activity (Futai, 1974), and that oxidative phosphorylation can be activated in CFPS systems (Jewett, et al., 2008).  
+
             Energy can also be derived from glutamate in the supplement solution (Jewett, et al., 2008), which is added in the form of magnesium glutamate and potassium glutamate. Glutamate is a metabolite in the tricarboxylic acid cycle, which generates NADH. In whole cells, NADH is used in oxidative phosphorylation to produce ATP. Oxidative phosphorylation relies on membrane bound proteins and proton gradients across a membrane. It has been shown previously that extracts prepared using French Press or sonication contain membrane vesicles which have ATPase activity (Futai, 1974), and that oxidative phosphorylation can be activated in CFPS systems (Jewett, et al., 2008).
 
             </br></br>
 
             </br></br>
             Sodium oxalate, another component of the supplement solution, is also used to help increase energy generation by the system. PEP synthetase, an enzyme present in E. coli, converts pyruvate into phosphoenol pyruvate (PEP) in a reaction which consumes ATP, thereby wasting ATP and directing it away from protein synthesis. Oxalate inhibits PEP synthetase by acting as a pyruvate mimic, and hence limit the energy wasted by this reaction.  
+
             Sodium oxalate, another component of the supplement solution, is also used to help increase energy generation by the system. PEP synthetase, an enzyme present in E. coli, converts pyruvate into phosphoenol pyruvate (PEP) in a reaction which consumes ATP, thereby wasting ATP and directing it away from protein synthesis. Oxalate inhibits PEP synthetase by acting as a pyruvate mimic, and hence limit the energy wasted by this reaction.
 +
            </br></br>
 +
            The ribonucleotides ATP, GTP, UTP, and CTP are also components of the supplement solution. They are used in the synthesis of mRNA for transcription of desired genes encoding on exogenous DNA added to the system, and ATP can also be used directly as energy for translation. The polyamines spermidine and putrescine are two other supplements which are added to aid with transcription. It is thought that they can bind proteins and DNA to help recruit polymerase for transcription. Polyamines may also increase translation fidelity, aid ribosome assembly, and activate tRNAs (Jelenc & Kurland, 1979; Jewett & Swartz, 2004b; Algranati & Goldemberg, 1977). To enable translation to occur, amino acids (added separately from the supplement solution) and an E. coli tRNA mixture are added to the CFPS system. Folinic acid is also added as it can be used as a source of folinate for the synthesis of f-Met; the amino acid required for initiation of translation in E. coli.
 
             </br></br>
 
             </br></br>
            The ribonucleotides ATP, GTP, UTP, and CTP are also components of the supplement solution. They are used in the synthesis of mRNA for transcription of desired genes encoding on exogenous DNA added to the system, and ATP can also be used directly as energy for translation. The polyamines spermidine and putrescine are two other supplements which are added to aid with transcription. It is thought that they can bind proteins and DNA to help recruit polymerase for transcription. Polyamines may also increase translation fidelity, aid ribosome assembly, and activate tRNAs (Jelenc & Kurland, 1979; Jewett & Swartz, 2004b; Algranati & Goldemberg, 1977). To enable translation to occur, amino acids (added separately from the supplement solution) and an E. coli tRNA mixture are added to the CFPS system. Folinic acid is also added as it can be used as a source of folinate for the synthesis of f-Met; the amino acid required for initiation of translation in E. coli.
 
            </br></br> 
 
 
             Magnesium and potassium ions are also added as supplements. Both ions are ubiquitous in cells with many functions in protein synthesis, namely aiding translation by associating with ribosome subunits and stabilising RNA (Nierhaus, 2014; Pyle, 2002). While magnesium ions are essential for protein synthesis, at high concentrations they can cause inhibition of ribosome translocation and hence inhibit protein synthesis (Borg & Ehrenberg, 2015). </p>
 
             Magnesium and potassium ions are also added as supplements. Both ions are ubiquitous in cells with many functions in protein synthesis, namely aiding translation by associating with ribosome subunits and stabilising RNA (Nierhaus, 2014; Pyle, 2002). While magnesium ions are essential for protein synthesis, at high concentrations they can cause inhibition of ribosome translocation and hence inhibit protein synthesis (Borg & Ehrenberg, 2015). </p>
         
+
 
 
           </div>
 
           </div>
         
+
 
 
           <p>Previous research has shown that the concentration of some components of the supplement solution are crucial for efficient protein synthesis, and that for each batch of extract produced the optimal concentration may need to be found (Yang, et al., 2012). Studies which have explored this have only focused on, at most, a few components at a time (Garamella, et al., 2016; Kelwick, et al., 2016), which means that important interactions between the components may have been missed. </p>
 
           <p>Previous research has shown that the concentration of some components of the supplement solution are crucial for efficient protein synthesis, and that for each batch of extract produced the optimal concentration may need to be found (Yang, et al., 2012). Studies which have explored this have only focused on, at most, a few components at a time (Garamella, et al., 2016; Kelwick, et al., 2016), which means that important interactions between the components may have been missed. </p>
         
+
 
 
           <h4 style="font-family: Rubik; text-align: left; margin-top: 1%"> Multifactorial Design of Experiments </h4>
 
           <h4 style="font-family: Rubik; text-align: left; margin-top: 1%"> Multifactorial Design of Experiments </h4>
 
           <p>Traditionally, biologists tend to use One Factor At a Time (OFAT) approaches to determine the effect and importance of factors on a system. This method can sometimes be a poor choice. By only determining the effect that a single factor has on a system at a time, important interactions can be missed. For example, removing only factor A may have no effect, and removing only factor B may also have no effect, but removing both may cause an adverse effect. Therefore, it is important to take a multifactorial approach when investigating the importance of conditions or components of a system, or when trying to optimise a system. An issue with this approach is that a large number of experiments may be required to fully investigate all factors. By using statistical methods, a Design of Experiments (DoE) can be determined which has the minimum number of experiments required to explore questions such as the importance of factors in a system. This approach also allows for robustness testing or determining batch-batch variation (Anderson & Whitcomb, 2010). As mentioned previously, CFPS systems can be plagued with issues rising from variation, so this approach offers a method to investigate the causes. There are several different types of DoE designs. One of these is the screening design (SD), which is used to create experimental designs to determine the factors with the highest effect on a system. Another design is the surface response design (SRD), which makes experimental designs to collect data for generating models which can predict optimal settings for many factors (SAS Institute Inc., 2016). Software tools, such as JMP (SAS Institute Inc., 2016), have been developed to create these experimental designs.</p>
 
           <p>Traditionally, biologists tend to use One Factor At a Time (OFAT) approaches to determine the effect and importance of factors on a system. This method can sometimes be a poor choice. By only determining the effect that a single factor has on a system at a time, important interactions can be missed. For example, removing only factor A may have no effect, and removing only factor B may also have no effect, but removing both may cause an adverse effect. Therefore, it is important to take a multifactorial approach when investigating the importance of conditions or components of a system, or when trying to optimise a system. An issue with this approach is that a large number of experiments may be required to fully investigate all factors. By using statistical methods, a Design of Experiments (DoE) can be determined which has the minimum number of experiments required to explore questions such as the importance of factors in a system. This approach also allows for robustness testing or determining batch-batch variation (Anderson & Whitcomb, 2010). As mentioned previously, CFPS systems can be plagued with issues rising from variation, so this approach offers a method to investigate the causes. There are several different types of DoE designs. One of these is the screening design (SD), which is used to create experimental designs to determine the factors with the highest effect on a system. Another design is the surface response design (SRD), which makes experimental designs to collect data for generating models which can predict optimal settings for many factors (SAS Institute Inc., 2016). Software tools, such as JMP (SAS Institute Inc., 2016), have been developed to create these experimental designs.</p>
Line 1,400: Line 1,429:
 
</div>
 
</div>
  
         
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Experimental Procedure 1</h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Experimental Procedure 1</h2>
 
           <p>Cell extracts were prepared from E. coli BL21 cells using sonication. A CFPS supplement premix solution was prepared as above, except the salts were omitted. Separate solutions for each salt were prepared and added to each CFPS reaction according to the main effects screening design. Reactions were performed as above and CFPS activity was measured as fluorescence at each time point minus fluorescence at 15 mins (Figure 3). Endpoint data was then used, along with the JMP software, to build a model predicting the important factors (Figure 4).
 
           <p>Cell extracts were prepared from E. coli BL21 cells using sonication. A CFPS supplement premix solution was prepared as above, except the salts were omitted. Separate solutions for each salt were prepared and added to each CFPS reaction according to the main effects screening design. Reactions were performed as above and CFPS activity was measured as fluorescence at each time point minus fluorescence at 15 mins (Figure 3). Endpoint data was then used, along with the JMP software, to build a model predicting the important factors (Figure 4).
Line 1,426: Line 1,455:
 
</table>
 
</table>
  
         
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Design Stage 2</h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Design Stage 2</h2>
  
Line 1,444: Line 1,473:
 
<p class="legend"><strong>Table 3:</strong> Table of reactions performed according to the DoE salt supplement surface response design. CFPS reactions contained concentrations of magnesium glutamate, potassium glutamate, and sodium oxalate, according to the table above. The pattern column shows how much of each supplement was present in a reaction; very low concentration (a), low concentration (−), usual concentration (0), high concentration (+), and very high concentration (A).</p>
 
<p class="legend"><strong>Table 3:</strong> Table of reactions performed according to the DoE salt supplement surface response design. CFPS reactions contained concentrations of magnesium glutamate, potassium glutamate, and sodium oxalate, according to the table above. The pattern column shows how much of each supplement was present in a reaction; very low concentration (a), low concentration (−), usual concentration (0), high concentration (+), and very high concentration (A).</p>
 
</div>
 
</div>
         
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Experimental Procedure 2</h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Experimental Procedure 2</h2>
 
           <p>Cell extracts were prepared and CFPS reactions performed as before, except the magnesium glutamate, potassium glutamate, and sodium oxalate concentrations were according to the surface response experimental design. Ammonium acetate was kept at the default amount. CFPS activity was measured as fluorescence at each time point minus fluorescence at 15 mins (Figure 6). Endpoint data was then used, along with the JMP software, to build a model predicting optimal concentrations for the three salts analysed (predictions visualised in figure 7). These predictions were then tested by preparing a supplement solution premix with amounts of magnesium glutamate, potassium glutamate, and sodium oxalate at concentrations of 6 mM, 195 mM, and 2 mM respectively. This supplement solution premix was used to supplement two batches of cell extract which were prepared identically. The first batch was the same extract used to collect data on which the predictions were made, whereas the second batch was newly prepared. It was found that for the first extract, CFPS activity was enhanced when the premix containing ‘optimised’ concentrations of salts was used compared to the un-altered supplement solution premix (Figure 8a). Additionally, CFPS activity was observed as being within the confidence intervals predicted by the DoE model.
 
           <p>Cell extracts were prepared and CFPS reactions performed as before, except the magnesium glutamate, potassium glutamate, and sodium oxalate concentrations were according to the surface response experimental design. Ammonium acetate was kept at the default amount. CFPS activity was measured as fluorescence at each time point minus fluorescence at 15 mins (Figure 6). Endpoint data was then used, along with the JMP software, to build a model predicting optimal concentrations for the three salts analysed (predictions visualised in figure 7). These predictions were then tested by preparing a supplement solution premix with amounts of magnesium glutamate, potassium glutamate, and sodium oxalate at concentrations of 6 mM, 195 mM, and 2 mM respectively. This supplement solution premix was used to supplement two batches of cell extract which were prepared identically. The first batch was the same extract used to collect data on which the predictions were made, whereas the second batch was newly prepared. It was found that for the first extract, CFPS activity was enhanced when the premix containing ‘optimised’ concentrations of salts was used compared to the un-altered supplement solution premix (Figure 8a). Additionally, CFPS activity was observed as being within the confidence intervals predicted by the DoE model.
Line 1,481: Line 1,510:
  
  
         
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Design Stage 3</h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Design Stage 3</h2>
 
           <p>All 15 supplements in the supplement solution premix were analysed similarly to how the four salts were initially analysed (i.e. a main effects screening design). A classical screening design was created with all supplements as continuous factors (the nucleotides UTP, GTP, and CTP were combined to form a single factor), and CFPS activity as the response to be maximised. A concentration of ‘0’ was used as the lower limit for each factor, and the concentration used normally in CFPS supplement premixes was used as the upper limit. The main effects screening design was then used to generate the experimental design (Table 4).
 
           <p>All 15 supplements in the supplement solution premix were analysed similarly to how the four salts were initially analysed (i.e. a main effects screening design). A classical screening design was created with all supplements as continuous factors (the nucleotides UTP, GTP, and CTP were combined to form a single factor), and CFPS activity as the response to be maximised. A concentration of ‘0’ was used as the lower limit for each factor, and the concentration used normally in CFPS supplement premixes was used as the upper limit. The main effects screening design was then used to generate the experimental design (Table 4).
Line 1,495: Line 1,524:
  
  
         
+
 
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Experimental Procedure 3</h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Experimental Procedure 3</h2>
 
           <p>CFPS reactions were prepared and performed as usual, except the supplement solution had components at concentrations according to the main effects screening design. The experiment was repeated using two separate batches of cell extract; one which was initially moderately active (extract one) and one which initially had low activity (extract two). The results for each are shown below. It can be seen that for extract 1, the CFPS reaction with the highest CFPS activity was that with the original premix composition (R21), suggesting that the supplement solution was already near optimal. This is not surprising as the extract was already showing moderately high activity. Conversely, for extract 2, the reaction using the original premix was not the one with the highest CFPS activity.
 
           <p>CFPS reactions were prepared and performed as usual, except the supplement solution had components at concentrations according to the main effects screening design. The experiment was repeated using two separate batches of cell extract; one which was initially moderately active (extract one) and one which initially had low activity (extract two). The results for each are shown below. It can be seen that for extract 1, the CFPS reaction with the highest CFPS activity was that with the original premix composition (R21), suggesting that the supplement solution was already near optimal. This is not surprising as the extract was already showing moderately high activity. Conversely, for extract 2, the reaction using the original premix was not the one with the highest CFPS activity.
Line 1,534: Line 1,563:
  
  
         
+
 
  
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Conclusions and Future Work </h2>
 
           <h2 style="font-family: Rubik; text-align: left; margin-top: 1%"> Conclusions and Future Work </h2>

Revision as of 15:42, 31 October 2017

spacefill

Our Experimental Results



Below is a diagram of our Sensynova Framework. Clicking on each part of the framework (e.g. detector modules) links to the relevant results.

Alternatively, at the bottom of this page are tabs which will show you results for every part of the project



Framework

Framework Chassis

Biochemical Adaptor

Target

Detector Modules

Multicellular Framework Testing

C12 HSL: Connector 1

Processor Modules

Framework in Cell Free Protein Synthesis Systems

C4 HSL: Connector 2

Reporter Modules



Looking for Interlab Study
related results? Click below!